Upload File

ncnp - b(& &É $ª 0¿ > e . @6õ4 (& $l h b Â1*...ncnp - b(& &É $ª 0¿...

  • Home
  • Documents
  • NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--
67
1987 2018 9 10 1566 1264 80.7% 246 15.7% 2767 2609 1725 66.1% 928 35.6% 791 30.3% 777 29.8% 386 14.8% 303 11.6% MDMA 250 9.6% 238 9.1% MDMA 207 7.9% 74 2.8% 805 30.9% 787 30.2% 409 15.7% 241 9.2% 118 4.5% 81 3.1% 1462 56.0% 446 17.1% 157 6.0% 155 5.9% 133 5.1% 108 4.1% 73 2.8% 1 1 1149 44.0% 1 452 39.3% 343 29.9% 105 9.1% 68 5.9% 64 5.6% 49 4.3% 26 2.3% 14 1.2% - 75 -

Upload: others

Post on 06-Feb-2020

4 views

Category:

Documents


0 download

Report

TRANSCRIPT

Page 1: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

1987

2018 9 10

1566 1264 80.7% 246 15.7%27672609

1725 66.1% 928 35.6%791 30.3% 777 29.8% 386 14.8% 303 11.6%MDMA 250 9.6% 238 9.1% MDMA 207 7.9%

74 2.8% 80530.9% 787 30.2% 409 15.7% 241 9.2%

118 4.5% 81 3.1%1462 56.0% 446 17.1% 157 6.0%

155 5.9% 133 5.1% 108 4.1% 73 2.8% 1 1 1149

44.0% 1 45239.3% 343 29.9% 105 9.1% 68 5.9%

64 5.6% 49 4.3% 26 2.3% 14 1.2%

- 75 -

Page 2: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

2018

1.

45125 6659 83

1,313 1,566

2.

1)2018 9 1

10 31 2

2)2018 7

8

1)

2018 11 30 11

FAX

2019 1

3)

ICD-10

ICD-10 F1

ICD-10

2018

4)

11)

a b

20

1990

3

5

1990

1

5-Meo-DIPT

Matsumoto 2016

2012 2014

Tanibuchi 2018

2011

40 War on Drug

HIV

2016 4UNGASS

2016 612

1987

- 76 -

Page 3: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

2018

1.

45125 6659 83

1,313 1,566

2.

1)2018 9 1

10 31 2

2)2018 7

8

1)

2018 11 30 11

FAX

2019 1

3)

ICD-10

ICD-10 F1

ICD-10

2018

4)

11)

a b

20

1990

3

5

1990

1

5-Meo-DIPT

Matsumoto 2016

2012 2014

Tanibuchi 2018

2011

40 War on Drug

HIV

2016 4UNGASS

2016 612

1987

- 77 -

Page 4: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

ICD-10

516 19.8%1627

62.4%

2) 3

1725 66.1% 92835.6% 791 30.3%

777 29.8% 38614.8% 303 11.6% MDMA 250

9.6% 238 9.1% MDMA207 7.9%

74 2.8% 702.7% ADHD 58 2.2%

371.4% 76 2.9%

3) 4

805 30.9%787 30.2%

409 15.7% 241 9.2%118 4.5% 81

3.1% 34 1.3% MDMA20 0.8% MDMA 14 0.6%

14 0.5%

11 0.4% ADHD 11 0.4%4 0.2% 3 0.1%

4) 5

1462 56.0%446 17.1% 157

6.0% 155 5.9% 1335.1% 108 4.1%

73 2.8% 34 1.3% ADHD13 0.5%10 0.4%

9 0.3%4 0.2% 3 0.1% MDMA

1 0.0% MDMA 1 0.0%

5) ICD-10 F1 6ICD-10 F1

F1x. 0 652.5% F1x. 1 320 12.3%

F1x. 2 1509 57.8% F1x. 3 43 1.6% F1x. 4

41 1.6% F1x. 5413 15.8% F1x. 6

33 1.3% F1x. 7858 32.9% F1x. 8

27 1.0%

6) ICD-10 7

ICD-10 F3 41015.7% F4

330 12.6% F2278 10.7% F6

269 10.3%F7 124 4.8%F8 113 4.3% F5

35 3.3% F981 3.1% F0

52 2.0%

7) 8

170 6.5%

DSM-5 93 3.6%DSM-5 36 1.4%

DSM-5 21 0.8%DSM-5 4 0.2%

32 1.2%

8) 9

cdef MDMA g MDMA hijkl

m ADHD Attention-Deficit / Hyperactive disorder

n o

5)

1 1

: 1

:

3.

A2018-028

15661264 80.7%

101865.0%246 15.7%2767

522715

1 2715

2609

1. 2609

1) 22609

1839 70.5% 769 29.5%1 0.0%

1034 1.3% 20 238 9.1% 30 658

25.2% 40 848 32.5% 50 55221.2% 60 193 7.4% 70

86 3.3% 30 50

112443.1%

680 26.1%

1337 51.2%

569 21.8%

1013 38.8%

- 78 -

Page 5: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

ICD-10

516 19.8%1627

62.4%

2) 3

1725 66.1% 92835.6% 791 30.3%

777 29.8% 38614.8% 303 11.6% MDMA 250

9.6% 238 9.1% MDMA207 7.9%

74 2.8% 702.7% ADHD 58 2.2%

371.4% 76 2.9%

3) 4

805 30.9%787 30.2%

409 15.7% 241 9.2%118 4.5% 81

3.1% 34 1.3% MDMA20 0.8% MDMA 14 0.6%

14 0.5%

11 0.4% ADHD 11 0.4%4 0.2% 3 0.1%

4) 5

1462 56.0%446 17.1% 157

6.0% 155 5.9% 1335.1% 108 4.1%

73 2.8% 34 1.3% ADHD13 0.5%10 0.4%

9 0.3%4 0.2% 3 0.1% MDMA

1 0.0% MDMA 1 0.0%

5) ICD-10 F1 6ICD-10 F1

F1x. 0 652.5% F1x. 1 320 12.3%

F1x. 2 1509 57.8% F1x. 3 43 1.6% F1x. 4

41 1.6% F1x. 5413 15.8% F1x. 6

33 1.3% F1x. 7858 32.9% F1x. 8

27 1.0%

6) ICD-10 7

ICD-10 F3 41015.7% F4

330 12.6% F2278 10.7% F6

269 10.3%F7 124 4.8%F8 113 4.3% F5

35 3.3% F981 3.1% F0

52 2.0%

7) 8

170 6.5%

DSM-5 93 3.6%DSM-5 36 1.4%

DSM-5 21 0.8%DSM-5 4 0.2%

32 1.2%

8) 9

cdef MDMA g MDMA hijkl

m ADHD Attention-Deficit / Hyperactive disorder

n o

5)

1 1

: 1

:

3.

A2018-028

15661264 80.7%

101865.0%246 15.7%2767

522715

1 2715

2609

1. 2609

1) 22609

1839 70.5% 769 29.5%1 0.0%

1034 1.3% 20 238 9.1% 30 658

25.2% 40 848 32.5% 50 55221.2% 60 193 7.4% 70

86 3.3% 30 50

112443.1%

680 26.1%

1337 51.2%

569 21.8%

1013 38.8%

- 79 -

Page 6: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

13 ICD-10

F1 13

F1x.024.9%

F1x. 122.2%

24.9%F1x. 2

73.3% 80.6%F1x. 3

F1x. 4F1x. 3

33.3%; 0.0%F1x. 3 22.2%; F1x. 4 0.0%

F1x. 3 3.4%; F1x. 4 5.4%F1x. 3 5.8%; F1x. 4 2.6%

F1x. 520.7% 18.5% 17.2%

15.1%F1x. 6

F1x. 744.8%

52.9%

13) ICD-1014

ICD-10 14

1 2F2

F3

F219.4%

F8 11.1%

F426.7%, 25.8% F6

14.3%, 18.7%

14) 15

11.0% 9.9%10.3%

3.8%3.9%

15) 16

2.7%, 7.4%4.5%,

5.6% 5.3%, 6.5%

6

1 41

2. 1 1149

1) 1 172609 1

11149 44.0%

1149

1731 63.6% 417

95 3.6%82 3.1%

54 2.1%

6 0.2% 90 3.4%

9)10

10

42.4% 34.0%

22.3%16.6%

44.4%

31.5%

65.4%47.4% 43.6%41.4%

10) 11

49.9% 36.7%

20.0%22.2%

38.3% 15.8%12.0%

11) 12

12

90.4%, 92.6%

47.8%, 60.0%30

5020 30

31.4%, 22.9%64.8% 68.5%

67.3% 66.5%

39.8%39.7%23.1% 18.5%

73.2%43.3% 49.1%

37.6% 27.8% 25.2%

56.4%43.3%

2 3

79.0%

12) ICD-10 F1

- 80 -

Page 7: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

13 ICD-10

F1 13

F1x.024.9%

F1x. 122.2%

24.9%F1x. 2

73.3% 80.6%F1x. 3

F1x. 4F1x. 3

33.3%; 0.0%F1x. 3 22.2%; F1x. 4 0.0%

F1x. 3 3.4%; F1x. 4 5.4%F1x. 3 5.8%; F1x. 4 2.6%

F1x. 520.7% 18.5% 17.2%

15.1%F1x. 6

F1x. 744.8%

52.9%

13) ICD-1014

ICD-10 14

1 2F2

F3

F219.4%

F8 11.1%

F426.7%, 25.8% F6

14.3%, 18.7%

14) 15

11.0% 9.9%10.3%

3.8%3.9%

15) 16

2.7%, 7.4%4.5%,

5.6% 5.3%, 6.5%

6

1 41

2. 1 1149

1) 1 172609 1

11149 44.0%

1149

1731 63.6% 417

95 3.6%82 3.1%

54 2.1%

6 0.2% 90 3.4%

9)10

10

42.4% 34.0%

22.3%16.6%

44.4%

31.5%

65.4%47.4% 43.6%41.4%

10) 11

49.9% 36.7%

20.0%22.2%

38.3% 15.8%12.0%

11) 12

12

90.4%, 92.6%

47.8%, 60.0%30

5020 30

31.4%, 22.9%64.8% 68.5%

67.3% 66.5%

39.8%39.7%23.1% 18.5%

73.2%43.3% 49.1%

37.6% 27.8% 25.2%

56.4%43.3%

2 3

79.0%

12) ICD-10 F1

- 81 -

Page 8: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

71.1% F1x. 3 38 3.3%F1x. 4 39 3.4%F1x. 5 199 17.3% F1x.

6 16 1.4% F1x. 7132 11.5%

F1x. 8 141.2%

1ICD-10 F1

F1x. 2F1x. 7

6) 1ICD-10 22

1ICD-10 F3 104

19.1% F4

178 15.5% F6130 11.3% F2

104 9.1%F8 62 5.4% F7

46 4.0% F541

3.6% F939 3.4% F0

20 3.4%

1ICD-10

7) 123

183 7.2%

DSM-5 33 2.9%DSM-5 21 1.8%

DSM-5 11 1.0%DSM-5 2 0.2%

22 1.9%1

8) 241

54 4.7%

48 4.2% 48 4.2%

2 0.2%29 2.5%

1

9) 125

1

25

49.0% 55.2%

30 5020 30

16.3% 62.5% 68.5%65.3% 64.8%

45.3%

76.3%

22.4% 26.6%

49.8% 44.9%

2 379.6% 78.6%

85.7%

36.3% 1 0.1% 110 30

2.6% 20 170 14.8% 30 34229.8% 40 328 28.5% 50 184

16.0% 60 52 4.5% 7043 3.7% 20 50

60452.6%

362 31.5% 1

1

491 42.7%

178 15.5%

310 27.0%

ICD-10

249 21.7%

668 58.1%

2) 118

1

594 51.7%517 45.0% 362 31.5%

304 26.5% 19517.0% 169 14.7% MDMA

116 10.1% 107 9.3%MDMA 98 8.5%

45 3.9% 30 2.6% ADHD 26

2.3%

25 2.2% 575.0%

3) 119

1298

25.9%

257 22.4%243 21.1% 131 11.4%

77 6.7% 33 3.4%21 1.8% MDMA 13

1.1% MDMA 8 0.7%10 0.9%

8 0.7%ADHD 6 0.5% 3 0.3%

2 0.2%

4) 120

1452

39.3%343 29.9% 105 9.1%68 5.9% 64 5.6%

49 4.3% 26 2.3%14 1.2%

8 0.7%7 0.6% ADHD

5 0.4% 4 0.3%3 0.3% MDMA 1

0.1% MDMA1

1

5) 1 ICD-10F1 21

1 ICD-10 F1F1x. 0

55 4.8% F1x. 1219 19.1% F1x. 2 817

- 82 -

Page 9: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

71.1% F1x. 3 38 3.3%F1x. 4 39 3.4%F1x. 5 199 17.3% F1x.

6 16 1.4% F1x. 7132 11.5%

F1x. 8 141.2%

1ICD-10 F1

F1x. 2F1x. 7

6) 1ICD-10 22

1ICD-10 F3 104

19.1% F4

178 15.5% F6130 11.3% F2

104 9.1%F8 62 5.4% F7

46 4.0% F541

3.6% F939 3.4% F0

20 3.4%

1ICD-10

7) 123

183 7.2%

DSM-5 33 2.9%DSM-5 21 1.8%

DSM-5 11 1.0%DSM-5 2 0.2%

22 1.9%1

8) 241

54 4.7%

48 4.2% 48 4.2%

2 0.2%29 2.5%

1

9) 125

1

25

49.0% 55.2%

30 5020 30

16.3% 62.5% 68.5%65.3% 64.8%

45.3%

76.3%

22.4% 26.6%

49.8% 44.9%

2 379.6% 78.6%

85.7%

36.3% 1 0.1% 110 30

2.6% 20 170 14.8% 30 34229.8% 40 328 28.5% 50 184

16.0% 60 52 4.5% 7043 3.7% 20 50

60452.6%

362 31.5% 1

1

491 42.7%

178 15.5%

310 27.0%

ICD-10

249 21.7%

668 58.1%

2) 118

1

594 51.7%517 45.0% 362 31.5%

304 26.5% 19517.0% 169 14.7% MDMA

116 10.1% 107 9.3%MDMA 98 8.5%

45 3.9% 30 2.6% ADHD 26

2.3%

25 2.2% 575.0%

3) 119

1298

25.9%

257 22.4%243 21.1% 131 11.4%

77 6.7% 33 3.4%21 1.8% MDMA 13

1.1% MDMA 8 0.7%10 0.9%

8 0.7%ADHD 6 0.5% 3 0.3%

2 0.2%

4) 120

1452

39.3%343 29.9% 105 9.1%68 5.9% 64 5.6%

49 4.3% 26 2.3%14 1.2%

8 0.7%7 0.6% ADHD

5 0.4% 4 0.3%3 0.3% MDMA 1

0.1% MDMA1

1

5) 1 ICD-10F1 21

1 ICD-10 F1F1x. 0

55 4.8% F1x. 1219 19.1% F1x. 2 817

- 83 -

Page 10: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

F424.2%, 27.6% F6

13.1%, 21.0%

13) 129

1

3.8%

14) 130

7.5%; 12.5%8.2%,

6.3% 8.8%, 9.4%

2

1 11

3. 1

1) 31

108 1N=64

N=44

2) 32

1

32

60.9%, 59.1%25.0%,

27.3%14.1%, 6.8%

3) ICD-10 F1 33ICD-10 F1

133 91

38.6%14.1% F1x.7

p=0.003

4) ICD-10 34 ICD-10 F0,

F2 F9 134

29.5%12.5% F2

p=0.028

5) 35

1

p=0.015 12.5%0.0%

4.

1)36

236

2016 11243

10) 126

1

2654.2% 27.2% 11.9%

9.1%

57.1%42.2%

29.7% 25.0%

75.0% 25.0%

66.7% MDMA1

100%42.9%

14.3%

79.0%33.2%

50.0% 37.5%

71.4%28.6%

71.4%23.8%

9.5% ADHD50.0%

20.0%

11) 1ICD-10 F1 27

1

ICD-10 F127

F1x. 07.9%

12.5% F1x. 1

25.0% 24.9%25.0%

28.6% 23.8%F1x. 2

76.4% 79.0%

60.9% F1x. 3 F1x. 4

33.3%; 0.0%14.3%; 0.0%

4.4%; 7.0%7.6%; 3.8%

F1x. 528.8% 26.5% 21.9%

F1x. 6

3.1%F1x. 7

24.5%

12) 1ICD-10 28

1ICD-10

28

1 2F3

16.3% 12.5%28.6% F2

F8 10.9%

- 84 -

Page 11: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

F424.2%, 27.6% F6

13.1%, 21.0%

13) 129

1

3.8%

14) 130

7.5%; 12.5%8.2%,

6.3% 8.8%, 9.4%

2

1 11

3. 1

1) 31

108 1N=64

N=44

2) 32

1

32

60.9%, 59.1%25.0%,

27.3%14.1%, 6.8%

3) ICD-10 F1 33ICD-10 F1

133 91

38.6%14.1% F1x.7

p=0.003

4) ICD-10 34 ICD-10 F0,

F2 F9 134

29.5%12.5% F2

p=0.028

5) 35

1

p=0.015 12.5%0.0%

4.

1)36

236

2016 11243

10) 126

1

2654.2% 27.2% 11.9%

9.1%

57.1%42.2%

29.7% 25.0%

75.0% 25.0%

66.7% MDMA1

100%42.9%

14.3%

79.0%33.2%

50.0% 37.5%

71.4%28.6%

71.4%23.8%

9.5% ADHD50.0%

20.0%

11) 1ICD-10 F1 27

1

ICD-10 F127

F1x. 07.9%

12.5% F1x. 1

25.0% 24.9%25.0%

28.6% 23.8%F1x. 2

76.4% 79.0%

60.9% F1x. 3 F1x. 4

33.3%; 0.0%14.3%; 0.0%

4.4%; 7.0%7.6%; 3.8%

F1x. 528.8% 26.5% 21.9%

F1x. 6

3.1%F1x. 7

24.5%

12) 1ICD-10 28

1ICD-10

28

1 2F3

16.3% 12.5%28.6% F2

F8 10.9%

- 85 -

Page 12: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

37.1%: 2016 35.6%: 201817.6: 2016 14.8%: 2018

17.7%: 2016 4.3%:

2018 2.5%: 2016 1.2%: 2018

4 51990

2000

20122014

3.

2016 3.6% 2018 4.1%2016 5.2% 2018 5.9%

2016 28.6% 2018 30.3%2016 10.4% 2018 11.6%

1

2016 4.9% 2018 5.6%2016 8.2% 2018 9.1%

2014

4.

20 30

ICD-10 F1

1

1ICD-10 F1

1

188 154111

4

58 4845

4239 35

8

2) 372

37

2016:

158

34 3216

1987

1

2609 , 2017 2262

11149 1164

2016

1.

2 146256.0%

446 17.1%157 6.0% 155 5.9%

133 5.1% 108 4.1%73 2.8% 1

3452 39.3%

343 29.9%105 9.1%

2.

2018

8.5%: 2016 6.0%: 20184.5%: 2016 2.8%: 2018

- 86 -

Page 13: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

37.1%: 2016 35.6%: 201817.6: 2016 14.8%: 2018

17.7%: 2016 4.3%:

2018 2.5%: 2016 1.2%: 2018

4 51990

2000

20122014

3.

2016 3.6% 2018 4.1%2016 5.2% 2018 5.9%

2016 28.6% 2018 30.3%2016 10.4% 2018 11.6%

1

2016 4.9% 2018 5.6%2016 8.2% 2018 9.1%

2014

4.

20 30

ICD-10 F1

1

1ICD-10 F1

1

188 154111

4

58 4845

4239 35

8

2) 372

37

2016:

158

34 3216

1987

1

2609 , 2017 2262

11149 1164

2016

1.

2 146256.0%

446 17.1%157 6.0% 155 5.9%

133 5.1% 108 4.1%73 2.8% 1

3452 39.3%

343 29.9%105 9.1%

2.

2018

8.5%: 2016 6.0%: 20184.5%: 2016 2.8%: 2018

- 87 -

Page 14: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

21

3

ex. AS

2016

6.2013 DSM-5

IR

6.5%DSM-5 3.6%

DSM-50.8% DSM-5 1.4%

DSM-5 0.2%

SOGS South Oaks Gambling Screen, 2017

0.8%3.6%

21

1

2

5.

1

8 2010

4

2016

10

8

1980

- 88 -

Page 15: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

21

3

ex. AS

2016

6.2013 DSM-5

IR

6.5%DSM-5 3.6%

DSM-50.8% DSM-5 1.4%

DSM-5 0.2%

SOGS South Oaks Gambling Screen, 2017

0.8%3.6%

21

1

2

5.

1

8 2010

4

2016

10

8

1980

- 89 -

Page 16: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

15661264 80.7% 246

15.7% 2767

2609

1462 56.0%446 17.1%

157 6.0% 155 5.9%133 5.1% 108 4.1%

73 2.8%1

1 114944.0% 1

45239.3%343 29.9% 105 9.1%68 5.9% 64 5.6%49 4.3% 26 2.3%

14 1.2%

1.1) Takano A, Miyamoto Y, Kawakami N,

Matsumoto T: Web-Based cognitivebehavioral relapse prevention program with tailored feedback for people with methamphetamine and other drug use problems: Development and Usability Study. JMIR Mental Health 3: 1-17, 2016.

2) Okumura Y, Shimizu S, Matsumoto T:Prevalence, prescribed quantities, andtrajectory of multipleprescriber episodes for benzodiazepines: A 2-year cohort study. Drug and Alcohol Dependence 158:118-25, 2016.

3) Matsumoto T, Tachimori H, Takano A,Tanibuchi Y, Funada D, Wada K: Recentchanges in the clinical features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014. Psychiatry and Clinical Neurosciences, 70: 560–566, 2016.

4) : STEM

51(1)26-37 2016

5)

: SMARPP

1 51(1) 38-54

2016 6)

DARCSMARPP

51 6414-424 2016

7) :

51(5) 335-347 2016 8)

26 11-24 2017

7.2016 6

2017 12

2.1%3.1%

3.6%

58 2

60.2%

ICD-10 F1x. 2

6964 3 2

4 1 1 ?

6 1

10

3.4%

8.

20

38

- 90 -

Page 17: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

15661264 80.7% 246

15.7% 2767

2609

1462 56.0%446 17.1%

157 6.0% 155 5.9%133 5.1% 108 4.1%

73 2.8%1

1 114944.0% 1

45239.3%343 29.9% 105 9.1%68 5.9% 64 5.6%49 4.3% 26 2.3%

14 1.2%

1.1) Takano A, Miyamoto Y, Kawakami N,

Matsumoto T: Web-Based cognitivebehavioral relapse prevention program with tailored feedback for people with methamphetamine and other drug use problems: Development and Usability Study. JMIR Mental Health 3: 1-17, 2016.

2) Okumura Y, Shimizu S, Matsumoto T:Prevalence, prescribed quantities, andtrajectory of multipleprescriber episodes for benzodiazepines: A 2-year cohort study. Drug and Alcohol Dependence 158:118-25, 2016.

3) Matsumoto T, Tachimori H, Takano A,Tanibuchi Y, Funada D, Wada K: Recentchanges in the clinical features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014. Psychiatry and Clinical Neurosciences, 70: 560–566, 2016.

4) : STEM

51(1)26-37 2016

5)

: SMARPP

1 51(1) 38-54

2016 6)

DARCSMARPP

51 6414-424 2016

7) :

51(5) 335-347 2016 8)

26 11-24 2017

7.2016 6

2017 12

2.1%3.1%

3.6%

58 2

60.2%

ICD-10 F1x. 2

6964 3 2

4 1 1 ?

6 1

10

3.4%

8.

20

38

- 91 -

Page 18: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

53(2) 83-942018.

37)

5385) 212-225 2018.38) 23(2)

121-129 2018.39)

33(4) 435-440 2018.40)

1(2) 12-15 2018.41)

2012 2014120(5): 361-368 2018.

42)

38(8) 844-846 2018.

43) 47(7) 799-804 2018.

44)

33(8) 959-964 2018.45) Pros and

Cons: Cons

60(9) 1019-1023 2018.46)

59(3) 278-282 2018.47)

202 40-46 2018.48)

Voice Bridge Project 20(1) 39-41 2018.

49) -- 33(6)

463-468 2018.50)

39(12) 1570-1578 2018.

51)

53(5) 151-170 2018.

52) Hiroko Kotajima-Murakami, AyumiTakano, Yasukazu Ogai, ShotaroTsukamoto, Maki Murakami, DaisukeFunada, Yuko Tanibuchi, HisateruTachimori, Kazushi Maruo, TsuyoshiSasaki, Toshihiko Matsumoto, KazutakaIkeda. Study of effects of ifenprodil inpatients with methamphetaminedependence: protocol for an exploratory,randomized, double-blind, placebo-controlled trial. NeuropsychopharmacolRep. 2019 (in press).

2.1) :

152016.5.20

2) :

1002016.6.17

3) : 38

2016.9.10 4) :

SMARPP 51

2016.10.8 5) :

? 51

2016.10.8 6) : SMARPP

51

2016.10.8 7) : SMARPP

72016.10.30

8) : SMARPP

342016.11.4

9) : 23

2016.11.27

9):

1 . 52(1): 34-55, 2017.

10)

52 5 141-155 2017.11) :

4808 19-23 2016 12) :

SMARPP 42(4) 571-579 2016

13) :

19(8) 1125-1136 201614) :

SMARPP

18(1) 123-125 201615) :

31(11) 1449-1454 11 2016

16) : 68(11) 10-11 2016

17) : 31(11) 1449-

1454 11 201618) , , : Voice Bridges

Project

. , 32(11): 1445-1451,2017.

19) 17 6 : 814-

817, 2017.20) 5.

3)

38 S137-S146 2017 21)

46(4): 437-442, 201722)

15(1): 49-57, 2017.23)

20(9): 975-982, 2017.24)

81(9): 730-736, 2017.

25)

No.39 2 -

- , 85-89, 2017.26)

No.39 2 -

- 90-94 2017.27)

Locomotive Pain Frontier 6(2): 46-47, 21017

28) 32(11): 1403-1404, 2017.

29)-

- 32(11): 1405-1412, 2017.

30)

32(11) : 1483-1491, 2017.31)

19 1 : 31-342017.

32)

119(12) 911-917 2017.33) , , ,

30 53-61 2017.34) Hamamura T, Suganuma S, Takano A,

Matsumoto T, Shimoyama H: The Efficacyof a Web-Based Screening and BriefIntervention for Reducing AlcoholConsumption Among Japanese ProblemDrinkers: Protocol for a Single-BlindRandomized Controlled Trial. JMIR Res.Protoc. 2018;7(5):e10650) doi:10.2196/10650

35) Tanibuchi Y, Matsumoto T, Funada D,Shimane T: The influence of tighteningregulations on patients with newpsychoactive substance-related disorders inJapan. Neuropsychopharmacol Rep. 2018Oct 19. doi: 10.1002/npr2.12035.

36)

- 92 -

Page 19: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

53(2) 83-942018.

37)

5385) 212-225 2018.38) 23(2)

121-129 2018.39)

33(4) 435-440 2018.40)

1(2) 12-15 2018.41)

2012 2014120(5): 361-368 2018.

42)

38(8) 844-846 2018.

43) 47(7) 799-804 2018.

44)

33(8) 959-964 2018.45) Pros and

Cons: Cons

60(9) 1019-1023 2018.46)

59(3) 278-282 2018.47)

202 40-46 2018.48)

Voice Bridge Project 20(1) 39-41 2018.

49) -- 33(6)

463-468 2018.50)

39(12) 1570-1578 2018.

51)

53(5) 151-170 2018.

52) Hiroko Kotajima-Murakami, AyumiTakano, Yasukazu Ogai, ShotaroTsukamoto, Maki Murakami, DaisukeFunada, Yuko Tanibuchi, HisateruTachimori, Kazushi Maruo, TsuyoshiSasaki, Toshihiko Matsumoto, KazutakaIkeda. Study of effects of ifenprodil inpatients with methamphetaminedependence: protocol for an exploratory,randomized, double-blind, placebo-controlled trial. NeuropsychopharmacolRep. 2019 (in press).

2.1) :

152016.5.20

2) :

1002016.6.17

3) : 38

2016.9.10 4) :

SMARPP 51

2016.10.8 5) :

? 51

2016.10.8 6) : SMARPP

51

2016.10.8 7) : SMARPP

72016.10.30

8) : SMARPP

342016.11.4

9) : 23

2016.11.27

9):

1 . 52(1): 34-55, 2017.

10)

52 5 141-155 2017.11) :

4808 19-23 2016 12) :

SMARPP 42(4) 571-579 2016

13) :

19(8) 1125-1136 201614) :

SMARPP

18(1) 123-125 201615) :

31(11) 1449-1454 11 2016

16) : 68(11) 10-11 2016

17) : 31(11) 1449-

1454 11 201618) , , : Voice Bridges

Project

. , 32(11): 1445-1451,2017.

19) 17 6 : 814-

817, 2017.20) 5.

3)

38 S137-S146 2017 21)

46(4): 437-442, 201722)

15(1): 49-57, 2017.23)

20(9): 975-982, 2017.24)

81(9): 730-736, 2017.

25)

No.39 2 -

- , 85-89, 2017.26)

No.39 2 -

- 90-94 2017.27)

Locomotive Pain Frontier 6(2): 46-47, 21017

28) 32(11): 1403-1404, 2017.

29)-

- 32(11): 1405-1412, 2017.

30)

32(11) : 1483-1491, 2017.31)

19 1 : 31-342017.

32)

119(12) 911-917 2017.33) , , ,

30 53-61 2017.34) Hamamura T, Suganuma S, Takano A,

Matsumoto T, Shimoyama H: The Efficacyof a Web-Based Screening and BriefIntervention for Reducing AlcoholConsumption Among Japanese ProblemDrinkers: Protocol for a Single-BlindRandomized Controlled Trial. JMIR Res.Protoc. 2018;7(5):e10650) doi:10.2196/10650

35) Tanibuchi Y, Matsumoto T, Funada D,Shimane T: The influence of tighteningregulations on patients with newpsychoactive substance-related disorders inJapan. Neuropsychopharmacol Rep. 2018Oct 19. doi: 10.1002/npr2.12035.

36)

- 93 -

Page 20: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

32)

1142018.6.22.

33)

Voice Bridges Project30

2018.9.10.34)

30

2018.9.10.35)

TC30

2018.9.10.36) Ayumi Takano, Yousuke Kumakura, Eriko

Ban, Takashi Usami, Toshihiko Matsumoto: Cohort study and development ofcommunity-based support for drug users onprobation in Japan, Voice Bridges Project.The 19th Congress of the InternationalSociety for Biomedical Research onAlcoholism, Kyoto, 2018.9.9-13.

37) Ayumi Takano, Sachiko Ono, HayatoYamana, Hiroki Matsui, ToshihikoMatsumoto, Hideo Yasunaga, NoritoKawakami : Risk factors for long-termprescription of benzodiazepine: cohortstudy using a large health insurance claimdatabase in Japan. The 19th Congress ofthe International Society for BiomedicalResearch on Alcoholism, Kyoto, 2018.9.9-13.

38) Ayumi Takano, Mitsuo Sase, ToshihikoMatsumoto, Norito Kawakami :Smartphone-based self-monitoringapplication for drug users: co-productionwith targeted users. The 19th Congress ofthe International Society for BiomedicalResearch on Alcoholism, Kyoto, 2018.9.9-13.

39)

26

2018.10.1140)

VoiceBridges Project 30

2018.9.9.41)

41

2018.10.5.42)

322018.10.23.

43)65

2018.10.25.44)

442018.10.28.

45)35

2018.12.1.46)

HIV

322018.12.4.

47) 1

252018.12.8.

.

()

1.

2.

3.

10):

51

2016.10.811) :

51

2016.10.812) :

2016.10.713) 2

232017.6.17

14) 35

1132017.6.23

15) 64

1132017.6.24

16) 5 51

2017.7.21.17)

3 2017.8.6.

18)8

Voice Bridges Project 29

2017.9.9.19) 9

29

2017.9.9.20)

22017.9.1.

21)1

2017.9.24.

22) 758

, 2017.10.6.23)

-31

2017.11.24.24) Takano A, Miyamoto Y, Matsumoto T,

Kawakami N Satisfaction and Usabilityof a Web-Based Relapse PreventionProgram for Japanese Drug Users the 21stEast Asian Forum of Nursing Scholars &11th International Nursing ConferenceKorea 2018.1.11-12.

25)

Voice Bridges Project37

2018.3.1-2.26)

372018.3.2.

27) Yuko Tanibuchi, Toshihiko Matsumoto,Daisuke Funada, Yasunari Kawasoe,Satoshi Sakakibara, Nobuya Naruse,Shunichiro Ikeda, Takashi Sunami, TakeoMuto, Tetsuji Cho A study on factors ofbetter treatment outcome for patients withnew psychoactive-substances-relateddisorders in specialized clinics or wards fordrug dependence in Japan The College onProblems of Drug dependence 80th AnnualScientific Meeting, San Diego, 2018.6.9-14.

28)33

Voice Bridges Project114

2018.6.21.29)

1142018.6.21.

30)33

1142018.6.21.

31)

Voice Bridges Project114

2018.6.22.

- 94 -

Page 21: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

32)

1142018.6.22.

33)

Voice Bridges Project30

2018.9.10.34)

30

2018.9.10.35)

TC30

2018.9.10.36) Ayumi Takano, Yousuke Kumakura, Eriko

Ban, Takashi Usami, Toshihiko Matsumoto: Cohort study and development ofcommunity-based support for drug users onprobation in Japan, Voice Bridges Project.The 19th Congress of the InternationalSociety for Biomedical Research onAlcoholism, Kyoto, 2018.9.9-13.

37) Ayumi Takano, Sachiko Ono, HayatoYamana, Hiroki Matsui, ToshihikoMatsumoto, Hideo Yasunaga, NoritoKawakami : Risk factors for long-termprescription of benzodiazepine: cohortstudy using a large health insurance claimdatabase in Japan. The 19th Congress ofthe International Society for BiomedicalResearch on Alcoholism, Kyoto, 2018.9.9-13.

38) Ayumi Takano, Mitsuo Sase, ToshihikoMatsumoto, Norito Kawakami :Smartphone-based self-monitoringapplication for drug users: co-productionwith targeted users. The 19th Congress ofthe International Society for BiomedicalResearch on Alcoholism, Kyoto, 2018.9.9-13.

39)

26

2018.10.1140)

VoiceBridges Project 30

2018.9.9.41)

41

2018.10.5.42)

322018.10.23.

43)65

2018.10.25.44)

442018.10.28.

45)35

2018.12.1.46)

HIV

322018.12.4.

47) 1

252018.12.8.

.

()

1.

2.

3.

10):

51

2016.10.811) :

51

2016.10.812) :

2016.10.713) 2

232017.6.17

14) 35

1132017.6.23

15) 64

1132017.6.24

16) 5 51

2017.7.21.17)

3 2017.8.6.

18)8

Voice Bridges Project 29

2017.9.9.19) 9

29

2017.9.9.20)

22017.9.1.

21)1

2017.9.24.

22) 758

, 2017.10.6.23)

-31

2017.11.24.24) Takano A, Miyamoto Y, Matsumoto T,

Kawakami N Satisfaction and Usabilityof a Web-Based Relapse PreventionProgram for Japanese Drug Users the 21stEast Asian Forum of Nursing Scholars &11th International Nursing ConferenceKorea 2018.1.11-12.

25)

Voice Bridges Project37

2018.3.1-2.26)

372018.3.2.

27) Yuko Tanibuchi, Toshihiko Matsumoto,Daisuke Funada, Yasunari Kawasoe,Satoshi Sakakibara, Nobuya Naruse,Shunichiro Ikeda, Takashi Sunami, TakeoMuto, Tetsuji Cho A study on factors ofbetter treatment outcome for patients withnew psychoactive-substances-relateddisorders in specialized clinics or wards fordrug dependence in Japan The College onProblems of Drug dependence 80th AnnualScientific Meeting, San Diego, 2018.6.9-14.

28)33

Voice Bridges Project114

2018.6.21.29)

1142018.6.21.

30)33

1142018.6.21.

31)

Voice Bridges Project114

2018.6.22.

- 95 -

Page 22: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

452.

9%39

86.7

%17

37.8

%29

118

.6%

2248

.9%

664.

2%56

84.8

%26

39.4

%1,

011

64.6

%30

45.5

%59

3.8%

5288

.1%

1220

.3%

271.

7%40

67.8

%83

5.3%

7185

.4%

1727

.0%

107

4.3%

4655

.4%

1,31

383

.8%

1,04

679

.7%

166

12.6

%1,

331

85.0

%88

067

.0%

1,56

6(1

00.0

%)

1,26

4(8

0.7%

)24

6(1

5.7%

)2,

767

(176

.7%

)1,

018

(65.

0%)

52

1

, 2017

, 2017.9.29. http://www.kurihama-

med.jp/news/20171004_tyousa.pdf2019.2.6

2017

28: 101-136

Matsumoto T, Tachimori H, Takano A et al.2016 Recent changes in the clinical

features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014. Psychiatry and Clinical Neurosciences 70: 560-566

Tanibuchi Y, Matsumoto T, Funada D, et al.2018 The influence of tightening

regulations on patients with new psychoactive substance-related disorders in Japan. Neuropsychopharmacol Rep. 2018 Oct 19. doi: 10.1002/npr2.12035.

- 96 -

Page 23: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

452.

9%39

86.7

%17

37.8

%29

118

.6%

2248

.9%

664.

2%56

84.8

%26

39.4

%1,

011

64.6

%30

45.5

%59

3.8%

5288

.1%

1220

.3%

271.

7%40

67.8

%83

5.3%

7185

.4%

1727

.0%

107

4.3%

4655

.4%

1,31

383

.8%

1,04

679

.7%

166

12.6

%1,

331

85.0

%88

067

.0%

1,56

6(1

00.0

%)

1,26

4(8

0.7%

)24

6(1

5.7%

)2,

767

(176

.7%

)1,

018

(65.

0%)

52

1 , 2017

, 2017.9.29. http://www.kurihama-

med.jp/news/20171004_tyousa.pdf2019.2.6

2017

28: 101-136

Matsumoto T, Tachimori H, Takano A et al.2016 Recent changes in the clinical

features of patients with new psychoactive-substances-related disorders in Japan: Comparison of the Nationwide Mental Hospital Surveys on Drug-related Psychiatric Disorders undertaken in 2012 and 2014. Psychiatry and Clinical Neurosciences 70: 560-566

Tanibuchi Y, Matsumoto T, Funada D, et al.2018 The influence of tightening

regulations on patients with new psychoactive substance-related disorders in Japan. Neuropsychopharmacol Rep. 2018 Oct 19. doi: 10.1002/npr2.12035.

- 97 -

Page 24: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%17

2566

.192

835

.679

130

.323

89.

170

2.7

MD

MA

250

9.6

MD

MA

207

7.9

386

14.8

777

29.8

742.

8

371.

4

303

11.6

AD

HD

582.

276

2.9

3:

N=2

609

%18

3970

.576

929

.51

0.0

1034

1.3

2023

89.

130

658

25.2

4084

832

.550

552

21.2

6019

37.

470

863.

311

2443

.168

026

.113

3751

.256

921

.810

1338

.851

619

.816

2762

.4

2:

N=2

609

- 98 -

Page 25: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%17

2566

.192

835

.679

130

.323

89.

170

2.7

MD

MA

250

9.6

MD

MA

207

7.9

386

14.8

777

29.8

742.

8

371.

4

303

11.6

AD

HD

582.

276

2.9

3:

N=2

609

%18

3970

.576

929

.51

0.0

1034

1.3

2023

89.

130

658

25.2

4084

832

.550

552

21.2

6019

37.

470

863.

311

2443

.168

026

.113

3751

.256

921

.810

1338

.851

619

.816

2762

.4

2:

N=2

609

- 99 -

Page 26: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%14

6256

.015

76.

010

84.

14

0.2

30.

1M

DM

A1

0.0

MD

MA

10.

073

2.8

446

17.1

100.

4

90.

3

155

5.9

AD

HD

130.

534

1.3

133

5.1

5:

N=2

609

%78

730

.280

530

.924

19.

24

0.2

30.

1M

DM

A16

0.6

MD

MA

200.

881

3.1

409

15.7

140.

5

110.

4

118

4.5

AD

HD

110.

434

1.3

552.

1

4:

N=2

609

- 100 -

Page 27: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%14

6256

.015

76.

010

84.

14

0.2

30.

1M

DM

A1

0.0

MD

MA

10.

073

2.8

446

17.1

100.

4

90.

3

155

5.9

AD

HD

130.

534

1.3

133

5.1

5:

N=2

609

%78

730

.280

530

.924

19.

24

0.2

30.

1M

DM

A16

0.6

MD

MA

200.

881

3.1

409

15.7

140.

5

110.

4

118

4.5

AD

HD

110.

434

1.3

552.

1

4:

N=2

609

- 101 -

Page 28: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%F0

522.

0F2

278

10.7

F341

015

.7F4

330

12.6

F585

3.3

F626

910

.3F7

124

4.8

F811

34.

3F9

813.

1

7:

ICD

-10

(N=2

609)

%F1

x. 0

652.

5F1

x. 1

320

12.3

F1x.

215

0957

.8F1

x. 3

431.

6F1

x. 4

411.

6F1

x. 5

413

15.8

F1x.

633

1.3

F1x.

785

832

.9F1

x. 8

271.

0

6:

ICD

-10

F1 (N

=260

9)

F1

- 102 -

Page 29: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%F0

522.

0F2

278

10.7

F341

015

.7F4

330

12.6

F585

3.3

F626

910

.3F7

124

4.8

F811

34.

3F9

813.

1

7:

ICD

-10

(N=2

609)

%F1

x. 0

652.

5F1

x. 1

320

12.3

F1x.

215

0957

.8F1

x. 3

431.

6F1

x. 4

411.

6F1

x. 5

413

15.8

F1x.

633

1.3

F1x.

785

832

.9F1

x. 8

271.

0

6:

ICD

-10

F1 (N

=260

9)

F1

- 103 -

Page 30: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%54

2.1

823.

195

3.6

60.

290

3.4

9:

(N=2

609)

%17

06.

5D

SM-5

933.

6D

SM-5

210.

8D

SM-5

361.

4D

SM-5

40.

232

1.2

8:

(N=2

609)

- 104 -

Page 31: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%54

2.1

823.

195

3.6

60.

290

3.4

9:

(N=2

609)

%17

06.

5D

SM-5

933.

6D

SM-5

210.

8D

SM-5

361.

4D

SM-5

40.

232

1.2

8:

(N=2

609)

- 105 -

Page 32: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

MD

MA

: A

DH

D2

dfp*

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

729

34

00

00

325

11

31

116

%49

.91.

93.

70.

00.

00.

00.

04.

15.

610

.011

.11.

97.

72.

912

.053

715

116

10

00

726

10

110

451

%36

.796

.214

.825

.00.

00.

00.

09.

65.

810

.00.

07.

10.

011

.838

.399

174

20

11

1014

00

131

421

%6.

80.

668

.550

.00.

010

0.0

100.

013

.73.

10.

00.

08.

47.

711

.815

.81

01

10

00

10

00

00

00

%0.

10.

00.

925

.00.

00.

00.

01.

40.

00.

00.

00.

00.

00.

00.

00

00

02

00

00

01

00

00

%0.

00.

00.

00.

066

.70.

00.

00.

00.

00.

011

.10.

00.

00.

00.

010

02

00

00

03

00

00

01

%0.

70.

01.

90.

00.

00.

00.

00.

00.

70.

00.

00.

00.

00.

00.

813

00

00

00

11

00

00

05

%0.

90.

00.

00.

00.

00.

00.

01.

40.

20.

00.

00.

00.

00.

03.

823

17

00

00

444

00

00

02

%1.

60.

66.

50.

00.

00.

00.

060

.30.

90.

00.

00.

00.

00.

01.

515

02

00

00

634

02

224

02

16%

1.0

0.0

1.9

0.0

0.0

0.0

0.0

8.2

76.2

20.0

22.2

15.5

0.0

5.9

12.0

00

00

00

00

64

11

00

2%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.3

40.0

11.1

0.6

0.0

0.0

1.5

21

00

00

00

10

31

01

2%

0.1

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.0

33.3

0.6

0.0

2.9

1.5

30

10

00

00

71

197

01

7%

0.2

0.0

0.9

0.0

0.0

0.0

0.0

0.0

1.6

10.0

11.1

62.6

0.0

2.9

5.3

10

00

00

00

20

01

70

0%

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.6

53.8

0.0

0.0

60

10

00

00

20

01

217

5%

0.4

0.0

0.9

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.6

15.4

50.0

3.8

230

00

10

01

151

03

24

5%

1.6

0.0

0.0

0.0

33.3

0.0

0.0

1.4

3.4

10.0

0.0

1.9

15.4

11.8

3.8

196

11:

N=2

609

p<0.

001

8268

.097

AD

HD

:

MD

MA

MD

MA

MD

MA

MD

MA

: A

DH

D2

dfp*

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

1462

3537

20

11

956

21

242

687

%10

0.0

22.3

34.3

50.0

0.0

100.

010

0.0

12.3

12.6

20.0

11.1

15.5

15.4

17.6

65.4

620

156

221

00

010

321

016

16

63%

42.4

99.4

20.4

25.0

0.0

0.0

0.0

13.7

7.2

10.0

0.0

10.3

7.7

17.6

47.4

497

2610

82

01

123

401

123

28

58%

34.0

16.6

100.

050

.00.

010

0.0

100.

031

.59.

010

.011

.114

.815

.423

.543

.617

02

204

00

04

120

03

11

21%

11.6

1.3

18.5

100.

00.

00.

00.

05.

52.

70.

00.

01.

97.

72.

915

.847

23

02

00

03

01

10

29

%3.

21.

32.

80.

066

.70.

00.

00.

00.

70.

011

.10.

60.

05.

96.

817

53

250

01

04

110

05

04

22%

12.0

1.9

23.1

0.0

0.0

100.

00.

05.

52.

50.

00.

03.

20.

011

.816

.513

35

260

01

14

91

03

02

22%

9.1

3.2

24.1

0.0

0.0

100.

010

0.0

5.5

2.0

10.0

0.0

1.9

0.0

5.9

16.5

203

648

00

10

7017

00

92

426

%13

.93.

844

.40.

00.

010

0.0

0.0

95.9

3.8

0.0

0.0

5.8

15.4

11.8

19.5

201

715

10

00

1143

33

243

24

55%

13.7

4.5

13.9

25.0

0.0

0.0

0.0

15.1

97.1

30.0

22.2

27.7

15.4

11.8

41.4

242

00

00

01

218

27

00

9%

1.6

1.3

0.0

0.0

0.0

0.0

0.0

1.4

4.7

80.0

22.2

4.5

0.0

0.0

6.8

112

10

10

00

51

74

03

2%

0.8

1.3

0.9

0.0

33.3

0.0

0.0

0.0

1.1

10.0

77.8

2.6

0.0

8.8

1.5

547

90

01

01

434

214

91

428

%3.

74.

58.

30.

00.

010

0.0

0.0

1.4

9.6

40.0

22.2

96.1

7.7

11.8

21.1

240

10

01

03

80

03

102

6%

1.6

0.0

0.9

0.0

0.0

100.

00.

04.

11.

80.

00.

01.

976

.95.

94.

517

21

01

00

013

00

32

2611

%1.

21.

30.

90.

033

.30.

00.

00.

02.

90.

00.

01.

915

.476

.58.

3

p<0.

001

p<0.

001

p<0.

001

p<0.

001

MD

MA

MD

MA

115.

130

141414

703.

243

14

p<0.

001

p<0.

001

p<0.

001

10:

N=2

609

99.2

33

1855

.163

118.

308

14

74.2

77

14 1456

2.79

5

408.

892

14

p<0.

001

: 42

3.77

514

p<0.

001

1215

. 267

14p<

0.00

1

537.

804

14p<

0.00

1

AD

HD

391.

936

14p<

0.00

1

1232

.345

14p<

0.00

1

257.

364

14p<

0.00

1

- 106 -

Page 33: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

MD

MA

: A

DH

D2

dfp*

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

729

34

00

00

325

11

31

116

%49

.91.

93.

70.

00.

00.

00.

04.

15.

610

.011

.11.

97.

72.

912

.053

715

116

10

00

726

10

110

451

%36

.796

.214

.825

.00.

00.

00.

09.

65.

810

.00.

07.

10.

011

.838

.399

174

20

11

1014

00

131

421

%6.

80.

668

.550

.00.

010

0.0

100.

013

.73.

10.

00.

08.

47.

711

.815

.81

01

10

00

10

00

00

00

%0.

10.

00.

925

.00.

00.

00.

01.

40.

00.

00.

00.

00.

00.

00.

00

00

02

00

00

01

00

00

%0.

00.

00.

00.

066

.70.

00.

00.

00.

00.

011

.10.

00.

00.

00.

010

02

00

00

03

00

00

01

%0.

70.

01.

90.

00.

00.

00.

00.

00.

70.

00.

00.

00.

00.

00.

813

00

00

00

11

00

00

05

%0.

90.

00.

00.

00.

00.

00.

01.

40.

20.

00.

00.

00.

00.

03.

823

17

00

00

444

00

00

02

%1.

60.

66.

50.

00.

00.

00.

060

.30.

90.

00.

00.

00.

00.

01.

515

02

00

00

634

02

224

02

16%

1.0

0.0

1.9

0.0

0.0

0.0

0.0

8.2

76.2

20.0

22.2

15.5

0.0

5.9

12.0

00

00

00

00

64

11

00

2%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

1.3

40.0

11.1

0.6

0.0

0.0

1.5

21

00

00

00

10

31

01

2%

0.1

0.6

0.0

0.0

0.0

0.0

0.0

0.0

0.2

0.0

33.3

0.6

0.0

2.9

1.5

30

10

00

00

71

197

01

7%

0.2

0.0

0.9

0.0

0.0

0.0

0.0

0.0

1.6

10.0

11.1

62.6

0.0

2.9

5.3

10

00

00

00

20

01

70

0%

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.6

53.8

0.0

0.0

60

10

00

00

20

01

217

5%

0.4

0.0

0.9

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.6

15.4

50.0

3.8

230

00

10

01

151

03

24

5%

1.6

0.0

0.0

0.0

33.3

0.0

0.0

1.4

3.4

10.0

0.0

1.9

15.4

11.8

3.8

196

11:

N=2

609

p<0.

001

8268

.097

AD

HD

:

MD

MA

MD

MA

MD

MA

MD

MA

: A

DH

D2

dfp*

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

1462

3537

20

11

956

21

242

687

%10

0.0

22.3

34.3

50.0

0.0

100.

010

0.0

12.3

12.6

20.0

11.1

15.5

15.4

17.6

65.4

620

156

221

00

010

321

016

16

63%

42.4

99.4

20.4

25.0

0.0

0.0

0.0

13.7

7.2

10.0

0.0

10.3

7.7

17.6

47.4

497

2610

82

01

123

401

123

28

58%

34.0

16.6

100.

050

.00.

010

0.0

100.

031

.59.

010

.011

.114

.815

.423

.543

.617

02

204

00

04

120

03

11

21%

11.6

1.3

18.5

100.

00.

00.

00.

05.

52.

70.

00.

01.

97.

72.

915

.847

23

02

00

03

01

10

29

%3.

21.

32.

80.

066

.70.

00.

00.

00.

70.

011

.10.

60.

05.

96.

817

53

250

01

04

110

05

04

22%

12.0

1.9

23.1

0.0

0.0

100.

00.

05.

52.

50.

00.

03.

20.

011

.816

.513

35

260

01

14

91

03

02

22%

9.1

3.2

24.1

0.0

0.0

100.

010

0.0

5.5

2.0

10.0

0.0

1.9

0.0

5.9

16.5

203

648

00

10

7017

00

92

426

%13

.93.

844

.40.

00.

010

0.0

0.0

95.9

3.8

0.0

0.0

5.8

15.4

11.8

19.5

201

715

10

00

1143

33

243

24

55%

13.7

4.5

13.9

25.0

0.0

0.0

0.0

15.1

97.1

30.0

22.2

27.7

15.4

11.8

41.4

242

00

00

01

218

27

00

9%

1.6

1.3

0.0

0.0

0.0

0.0

0.0

1.4

4.7

80.0

22.2

4.5

0.0

0.0

6.8

112

10

10

00

51

74

03

2%

0.8

1.3

0.9

0.0

33.3

0.0

0.0

0.0

1.1

10.0

77.8

2.6

0.0

8.8

1.5

547

90

01

01

434

214

91

428

%3.

74.

58.

30.

00.

010

0.0

0.0

1.4

9.6

40.0

22.2

96.1

7.7

11.8

21.1

240

10

01

03

80

03

102

6%

1.6

0.0

0.9

0.0

0.0

100.

00.

04.

11.

80.

00.

01.

976

.95.

94.

517

21

01

00

013

00

32

2611

%1.

21.

30.

90.

033

.30.

00.

00.

02.

90.

00.

01.

915

.476

.58.

3

p<0.

001

p<0.

001

p<0.

001

p<0.

001

MD

MA

MD

MA

115.

130

141414

703.

243

14

p<0.

001

p<0.

001

p<0.

001

10:

N=2

609

99.2

33

1855

.163

118.

308

14

74.2

77

14 1456

2.79

5

408.

892

14

p<0.

001

: 42

3.77

514

p<0.

001

1215

. 267

14p<

0.00

1

537.

804

14p<

0.00

1

AD

HD

391.

936

14p<

0.00

1

1232

.345

14p<

0.00

1

257.

364

14p<

0.00

1

- 107 -

Page 34: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

MD

MA

: A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

1086

142

100

43

11

6721

35

393

822

91%

74.3

90.4

92.6

100.

010

0.0

100.

010

0.0

91.8

47.8

50.0

33.3

60.0

61.5

64.7

68.4

376

158

00

00

623

35

662

511

42%

25.7

9.6

7.4

0.0

0.0

0.0

0.0

8.2

52.2

50.0

66.7

40.0

38.5

32.4

31.6

00

00

00

00

00

00

01

0%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.9

0.0

50

70

00

00

20

014

00

6%

0.3

0.0

6.5

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

9.0

0.0

0.0

4.5

896

223

10

016

492

028

25

15%

6.1

3.8

20.4

75.0

33.3

0.0

0.0

21.9

11.0

20.0

0.0

18.1

15.4

14.7

11.3

315

3553

00

00

3411

21

146

113

47%

21.5

22.3

49.1

0.0

0.0

0.0

0.0

46.6

25.1

10.0

11.1

29.7

7.7

38.2

35.3

510

5818

01

11

2013

53

445

78

37%

34.9

36.9

16.7

0.0

33.3

100.

010

0.0

27.4

30.3

30.0

44.4

29.0

53.8

23.5

27.8

377

406

11

00

377

13

152

521

%25

.825

.55.

625

.033

.30.

00.

04.

117

.310

.033

.39.

715

.414

.715

.812

518

20

00

00

381

13

11

3%

8.5

11.5

1.9

0.0

0.0

0.0

0.0

0.0

8.5

10.0

11.1

1.9

7.7

2.9

2.3

410

00

00

00

332

04

02

4%

2.8

0.0

0.0

0.0

0.0

0.0

0.0

0.0

7.4

20.0

0.0

2.6

0.0

5.9

3.0

459

3670

22

10

5030

06

810

39

2355

%31

.422

.964

.850

.066

.710

0.0

0.0

68.5

67.3

60.0

88.9

66.5

69.2

67.6

41.4

337

2943

31

01

2914

22

348

314

25%

23.1

18.5

39.8

75.0

33.3

0.0

100.

039

.731

.820

.033

.331

.023

.141

.218

.810

7068

532

10

019

392

012

34

64%

73.2

43.3

49.1

50.0

33.3

0.0

0.0

26.0

8.7

20.0

0.0

7.7

23.1

11.8

48.1

368

5930

00

10

1040

20

200

435

%25

.237

.627

.80.

00.

010

0.0

0.0

13.7

9.0

20.0

0.0

12.9

0.0

11.8

26.3

825

6816

01

00

729

10

91

551

%56

.443

.314

.80.

033

.30.

00.

09.

66.

510

.00.

05.

87.

714

.738

.327

834

171

10

010

993

234

59

23%

19.0

21.7

15.7

25.0

33.3

0.0

0.0

13.7

22.2

30.0

22.2

21.9

38.5

26.5

17.3

898

124

611

21

148

268

57

101

720

83%

61.4

79.0

56.5

25.0

66.7

100.

010

0.0

65.8

60.1

50.0

77.8

65.2

53.8

58.8

62.4

50

12:

N=2

609

2df

p*

289.

132

28p<

0.00

1

p=0.

069

14p<

0.00

1

60

70

335.

485

28

10

422.

443

84p<

0.00

1

20 30 40

103.

560

14p<

0.00

1

608.

370

28p<

0.00

1

22.2

2128

p=0.

771

39.7

6128

p<0.

001

55.3

20

786.

047

14p<

0.00

1

- 108 -

Page 35: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

MD

MA

:A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

95

00

00

03

331

08

05

1%

0.6

3.2

0.0

0.0

0.0

0.0

0.0

4.1

7.4

10.0

0.0

5.2

0.0

14.7

0.8

9415

241

01

012

111

33

301

916

%6.

49.

622

.225

.00.

010

0.0

0.0

16.4

24.9

30.0

33.3

19.4

7.7

26.5

12.0

763

7064

32

00

3932

76

412

56

1684

%52

.244

.659

.375

.066

.70.

00.

053

.473

.360

.044

.480

.646

.247

.163

.210

12

01

00

015

02

90

12

%0.

70.

61.

90.

033

.30.

00.

00.

03.

40.

022

.25.

80.

02.

91.

55

11

00

00

024

00

40

24

%0.

30.

60.

90.

00.

00.

00.

00.

05.

40.

00.

02.

60.

05.

93.

030

227

200

01

111

140

113

19

13%

20.7

17.2

18.5

0.0

0.0

100.

010

0.0

15.1

3.1

0.0

11.1

8.4

7.7

26.5

9.8

186

20

00

00

20

01

01

3%

1.2

3.8

1.9

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.6

0.0

2.9

2.3

655

8326

01

10

1913

01

24

647

%44

.852

.924

.10.

033

.310

0.0

0.0

26.0

2.9

0.0

11.1

1.3

30.8

17.6

35.3

13:

ICD

-10

F1N

=260

9

394.

717

p<0.

001

p<0.

001

p<0.

001

p<0.

001

p<0.

001

14 14 14 14 14 14 14 14

2df

p*

99.4

50

153.

335

p<0.

001

ICD

-10

F1x.

6

F1x.

7

F1x.

0

F1x.

1

F1x.

2

F1x.

3

F1x.

4

F1x.

5

*

115.

900

78.1

90

66.0

13

107.

935

14.6

57

p<0.

001

p=0.

472

MD

MA

MD

MA

: A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

1086

142

100

43

11

6721

35

393

822

91%

74.3

90.4

92.6

100.

010

0.0

100.

010

0.0

91.8

47.8

50.0

33.3

60.0

61.5

64.7

68.4

376

158

00

00

623

35

662

511

42%

25.7

9.6

7.4

0.0

0.0

0.0

0.0

8.2

52.2

50.0

66.7

40.0

38.5

32.4

31.6

00

00

00

00

00

00

01

0%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.9

0.0

50

70

00

00

20

014

00

6%

0.3

0.0

6.5

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

9.0

0.0

0.0

4.5

896

223

10

016

492

028

25

15%

6.1

3.8

20.4

75.0

33.3

0.0

0.0

21.9

11.0

20.0

0.0

18.1

15.4

14.7

11.3

315

3553

00

00

3411

21

146

113

47%

21.5

22.3

49.1

0.0

0.0

0.0

0.0

46.6

25.1

10.0

11.1

29.7

7.7

38.2

35.3

510

5818

01

11

2013

53

445

78

37%

34.9

36.9

16.7

0.0

33.3

100.

010

0.0

27.4

30.3

30.0

44.4

29.0

53.8

23.5

27.8

377

406

11

00

377

13

152

521

%25

.825

.55.

625

.033

.30.

00.

04.

117

.310

.033

.39.

715

.414

.715

.812

518

20

00

00

381

13

11

3%

8.5

11.5

1.9

0.0

0.0

0.0

0.0

0.0

8.5

10.0

11.1

1.9

7.7

2.9

2.3

410

00

00

00

332

04

02

4%

2.8

0.0

0.0

0.0

0.0

0.0

0.0

0.0

7.4

20.0

0.0

2.6

0.0

5.9

3.0

459

3670

22

10

5030

06

810

39

2355

%31

.422

.964

.850

.066

.710

0.0

0.0

68.5

67.3

60.0

88.9

66.5

69.2

67.6

41.4

337

2943

31

01

2914

22

348

314

25%

23.1

18.5

39.8

75.0

33.3

0.0

100.

039

.731

.820

.033

.331

.023

.141

.218

.810

7068

532

10

019

392

012

34

64%

73.2

43.3

49.1

50.0

33.3

0.0

0.0

26.0

8.7

20.0

0.0

7.7

23.1

11.8

48.1

368

5930

00

10

1040

20

200

435

%25

.237

.627

.80.

00.

010

0.0

0.0

13.7

9.0

20.0

0.0

12.9

0.0

11.8

26.3

825

6816

01

00

729

10

91

551

%56

.443

.314

.80.

033

.30.

00.

09.

66.

510

.00.

05.

87.

714

.738

.327

834

171

10

010

993

234

59

23%

19.0

21.7

15.7

25.0

33.3

0.0

0.0

13.7

22.2

30.0

22.2

21.9

38.5

26.5

17.3

898

124

611

21

148

268

57

101

720

83%

61.4

79.0

56.5

25.0

66.7

100.

010

0.0

65.8

60.1

50.0

77.8

65.2

53.8

58.8

62.4

50

12:

N=2

609

2df

p*

289.

132

28p<

0.00

1

p=0.

069

14p<

0.00

1

60

70

335.

485

28

10

422.

443

84p<

0.00

1

20 30 40

103.

560

14p<

0.00

1

608.

370

28p<

0.00

1

22.2

2128

p=0.

771

39.7

6128

p<0.

001

55.3

20

786.

047

14p<

0.00

1

- 109 -

Page 36: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

MD

MA

: A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

699

50

00

08

441

116

14

12%

4.7

5.7

4.6

0.0

0.0

0.0

0.0

11.0

9.9

10.0

11.1

10.3

7.7

11.8

9.0

507

30

00

05

170

05

01

5%

3.4

4.5

2.8

0.0

0.0

0.0

0.0

6.8

3.8

0.0

0.0

3.2

0.0

2.9

3.8

52

30

00

01

60

03

01

0%

0.3

1.3

2.8

0.0

0.0

0.0

0.0

1.4

1.3

0.0

0.0

1.9

0.0

2.9

0.0

61

10

00

02

170

06

01

2%

0.4

0.6

0.9

0.0

0.0

0.0

0.0

2.7

3.8

0.0

0.0

3.9

0.0

2.9

1.5

20

00

00

00

00

00

01

1%

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.9

0.8

120

00

00

02

91

12

10

4%

0.8

0.0

0.0

0.0

0.0

0.0

0.0

2.7

2.0

10.0

11.1

1.3

7.7

0.0

3.0

31.0

8214

p=0.

005

*

p<0.

001

21.9

0614

p=0.

081

26.8

8014

p=0.

020

4.63

914

p=0.

990

17.3

8114

p=0.

236

39.5

3814

15:

N=2

609

2df

p

MD

MA

MD

MA

:A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

255

10

00

00

100

01

04

6%

1.7

3.2

0.9

0.0

0.0

0.0

0.0

0.0

2.2

0.0

0.0

0.6

0.0

11.8

4.5

154

2621

00

10

1322

00

160

322

%10

.516

.619

.40.

00.

010

0.0

0.0

17.8

4.9

0.0

0.0

10.3

0.0

8.8

16.5

168

219

00

00

1512

14

730

37

25%

11.5

13.4

8.3

0.0

0.0

0.0

0.0

20.5

27.1

40.0

77.8

19.4

23.1

20.6

18.8

122

98

00

00

1011

93

040

24

13%

8.3

5.7

7.4

0.0

0.0

0.0

0.0

13.7

26.7

30.0

0.0

25.8

15.4

11.8

9.8

373

30

10

00

271

08

11

3%

2.5

1.9

2.8

0.0

33.3

0.0

0.0

0.0

6.1

10.0

0.0

5.2

7.7

2.9

2.3

125

166

00

00

364

01

292

617

%8.

510

.25.

60.

00.

00.

00.

04.

114

.30.

011

.118

.715

.417

.612

.882

150

00

00

310

10

70

06

%5.

69.

60.

00.

00.

00.

00.

04.

12.

210

.00.

04.

50.

00.

04.

543

712

00

00

326

10

131

25

%2.

94.

511

.10.

00.

00.

00.

04.

15.

810

.00.

08.

47.

75.

93.

848

52

20

00

110

00

71

05

%3.

33.

21.

950

.00.

00.

00.

01.

42.

20.

00.

04.

57.

70.

03.

8

2df

p

F027

.210

14

F530

.540

14

p=0.

018

F310

5.89

714

p<0.

001

F251

.936

14p<

0.00

1

p=0.

006

F414

4.28

414

p<0.

001

p=0.

001

F725

.915

14p=

0.02

7

*

14:

ICD

-10

N=2

609

F829

.631

14p=

0.00

9

F935

.781

14p=

0.00

1

F635

.682

14

- 110 -

Page 37: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

MD

MA

: A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

699

50

00

08

441

116

14

12%

4.7

5.7

4.6

0.0

0.0

0.0

0.0

11.0

9.9

10.0

11.1

10.3

7.7

11.8

9.0

507

30

00

05

170

05

01

5%

3.4

4.5

2.8

0.0

0.0

0.0

0.0

6.8

3.8

0.0

0.0

3.2

0.0

2.9

3.8

52

30

00

01

60

03

01

0%

0.3

1.3

2.8

0.0

0.0

0.0

0.0

1.4

1.3

0.0

0.0

1.9

0.0

2.9

0.0

61

10

00

02

170

06

01

2%

0.4

0.6

0.9

0.0

0.0

0.0

0.0

2.7

3.8

0.0

0.0

3.9

0.0

2.9

1.5

20

00

00

00

00

00

01

1%

0.1

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.9

0.8

120

00

00

02

91

12

10

4%

0.8

0.0

0.0

0.0

0.0

0.0

0.0

2.7

2.0

10.0

11.1

1.3

7.7

0.0

3.0

31.0

8214

p=0.

005

*

p<0.

001

21.9

0614

p=0.

081

26.8

8014

p=0.

020

4.63

914

p=0.

990

17.3

8114

p=0.

236

39.5

3814

15:

N=2

609

2df

p

MD

MA

MD

MA

:A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

255

10

00

00

100

01

04

6%

1.7

3.2

0.9

0.0

0.0

0.0

0.0

0.0

2.2

0.0

0.0

0.6

0.0

11.8

4.5

154

2621

00

10

1322

00

160

322

%10

.516

.619

.40.

00.

010

0.0

0.0

17.8

4.9

0.0

0.0

10.3

0.0

8.8

16.5

168

219

00

00

1512

14

730

37

25%

11.5

13.4

8.3

0.0

0.0

0.0

0.0

20.5

27.1

40.0

77.8

19.4

23.1

20.6

18.8

122

98

00

00

1011

93

040

24

13%

8.3

5.7

7.4

0.0

0.0

0.0

0.0

13.7

26.7

30.0

0.0

25.8

15.4

11.8

9.8

373

30

10

00

271

08

11

3%

2.5

1.9

2.8

0.0

33.3

0.0

0.0

0.0

6.1

10.0

0.0

5.2

7.7

2.9

2.3

125

166

00

00

364

01

292

617

%8.

510

.25.

60.

00.

00.

00.

04.

114

.30.

011

.118

.715

.417

.612

.882

150

00

00

310

10

70

06

%5.

69.

60.

00.

00.

00.

00.

04.

12.

210

.00.

04.

50.

00.

04.

543

712

00

00

326

10

131

25

%2.

94.

511

.10.

00.

00.

00.

04.

15.

810

.00.

08.

47.

75.

93.

848

52

20

00

110

00

71

05

%3.

33.

21.

950

.00.

00.

00.

01.

42.

20.

00.

04.

57.

70.

03.

8

2df

p

F027

.210

14

F530

.540

14

p=0.

018

F310

5.89

714

p<0.

001

F251

.936

14p<

0.00

1

p=0.

006

F414

4.28

414

p<0.

001

p=0.

001

F725

.915

14p=

0.02

7

*

14:

ICD

-10

N=2

609

F829

.631

14p=

0.00

9

F935

.781

14p=

0.00

1

F635

.682

14

- 111 -

Page 38: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%73

163

.641

736

.31

0.1

1030

2.6

2017

014

.830

342

29.8

4032

828

.550

184

16.0

6052

4.5

7043

3.7

604

52.6

362

31.5

491

42.7

178

15.5

310

27.0

249

21.7

668

58.1

17:

1N

=114

9MD

MA

MD

MA

: A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

390

81

00

03

00

01

00

2%

2.7

0.0

7.4

25.0

0.0

0.0

0.0

4.1

0.0

0.0

0.0

0.6

0.0

0.0

1.5

660

60

00

02

20

01

02

3%

4.5

0.0

5.6

0.0

0.0

0.0

0.0

2.7

0.4

0.0

0.0

0.6

0.0

5.9

2.3

782

70

00

00

20

01

10

4%

5.3

1.3

6.5

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.6

7.7

0.0

3.0

40

10

00

00

10

00

00

0%

0.3

0.0

0.9

0.0

0.0

0.0

0.0

0.0

0.2

0.0

0.0

0.0

0.0

0.0

0.0

59.0

7.0

6.0

0.0

0.0

0.0

0.0

2.0

3.0

1.0

0.0

5.0

1.0

0.0

6.0

%4.

04.

55.

60.

00.

00.

00.

02.

70.

710

.00.

03.

27.

70.

04.

518

.184

14p=

0.19

9

14p=

0.00

3

16:

2df

p*

39.7

3214

p<0.

001

3.76

914

p=0.

997

45.6

4014

p<0.

001

32.5

58

- 112 -

Page 39: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%73

163

.641

736

.31

0.1

1030

2.6

2017

014

.830

342

29.8

4032

828

.550

184

16.0

6052

4.5

7043

3.7

604

52.6

362

31.5

491

42.7

178

15.5

310

27.0

249

21.7

668

58.1

17:

1N

=114

9MD

MA

MD

MA

: A

DH

D

n=14

62n=

157

n=10

8n=

4n=

3n=

1n=

1n=

73n=

446

n=10

n=9

n=15

5n=

13n=

34n=

133

390

81

00

03

00

01

00

2%

2.7

0.0

7.4

25.0

0.0

0.0

0.0

4.1

0.0

0.0

0.0

0.6

0.0

0.0

1.5

660

60

00

02

20

01

02

3%

4.5

0.0

5.6

0.0

0.0

0.0

0.0

2.7

0.4

0.0

0.0

0.6

0.0

5.9

2.3

782

70

00

00

20

01

10

4%

5.3

1.3

6.5

0.0

0.0

0.0

0.0

0.0

0.4

0.0

0.0

0.6

7.7

0.0

3.0

40

10

00

00

10

00

00

0%

0.3

0.0

0.9

0.0

0.0

0.0

0.0

0.0

0.2

0.0

0.0

0.0

0.0

0.0

0.0

59.0

7.0

6.0

0.0

0.0

0.0

0.0

2.0

3.0

1.0

0.0

5.0

1.0

0.0

6.0

%4.

04.

55.

60.

00.

00.

00.

02.

70.

710

.00.

03.

27.

70.

04.

518

.184

14p=

0.19

9

14p=

0.00

3

16:

2df

p*

39.7

3214

p<0.

001

3.76

914

p=0.

997

45.6

4014

p<0.

001

32.5

58

- 113 -

Page 40: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%24

321

.125

722

.413

111

.42

0.2

30.

3M

DM

A8

0.7

MD

MA

131.

133

3.4

298

25.9

100.

9

80.

7

776.

7

AD

HD

60.

521

1.8

393.

4

19:

1N

=114

9

%59

451

.730

426

.536

231

.510

79.

330

2.6

MD

MA

116

10.1

MD

MA

988.

516

914

.751

745

.0

453.

9

252.

2

195

17.0

AD

HD

262.

357

5.0

18:

1N

=114

9

- 114 -

Page 41: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%24

321

.125

722

.413

111

.42

0.2

30.

3M

DM

A8

0.7

MD

MA

131.

133

3.4

298

25.9

100.

9

80.

7

776.

7

AD

HD

60.

521

1.8

393.

4

19:

1N

=114

9

%59

451

.730

426

.536

231

.510

79.

330

2.6

MD

MA

116

10.1

MD

MA

988.

516

914

.751

745

.0

453.

9

252.

2

195

17.0

AD

HD

262.

357

5.0

18:

1N

=114

9

- 115 -

Page 42: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%F1

x. 0

554.

8F1

x. 1

219

19.1

F1x.

281

771

.1F1

x. 3

383.

3F1

x. 4

393.

4F1

x. 5

199

17.3

F1x.

616

1.4

F1x.

713

211

.5F1

x. 8

141.

2

21:

1IC

D-1

0 F1

(N=1

149)

F1

%45

239

.349

4.3

645.

64

0.3

30.

3M

DM

A0

0.0

MD

MA

10.

114

1.2

343

29.9

80.

7

70.

6

105

9.1

AD

HD

50.

426

2.3

685.

9

20:

1N

=114

9

- 116 -

Page 43: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%F1

x. 0

554.

8F1

x. 1

219

19.1

F1x.

281

771

.1F1

x. 3

383.

3F1

x. 4

393.

4F1

x. 5

199

17.3

F1x.

616

1.4

F1x.

713

211

.5F1

x. 8

141.

2

21:

1IC

D-1

0 F1

(N=1

149)

F1

%45

239

.349

4.3

645.

64

0.3

30.

3M

DM

A0

0.0

MD

MA

10.

114

1.2

343

29.9

80.

7

70.

6

105

9.1

AD

HD

50.

426

2.3

685.

9

20:

1N

=114

9

- 117 -

Page 44: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%83

7.2

DSM

-533

2.9

DSM

-511

1.0

211.

82

0.2

221.

9

23:

1 (

N=1

149)

%F0

201.

7F2

104

9.1

F321

919

.1F4

178

15.5

F541

3.6

F613

011

.3F7

464.

0F8

625.

4F9

393.

4

22:

1IC

D-1

0 (N

=114

9)

- 118 -

Page 45: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%83

7.2

DSM

-533

2.9

DSM

-511

1.0

211.

82

0.2

221.

9

23:

1 (

N=1

149)

%F0

201.

7F2

104

9.1

F321

919

.1F4

178

15.5

F541

3.6

F613

011

.3F7

464.

0F8

625.

4F9

393.

4

22:

1IC

D-1

0 (N

=114

9)

- 119 -

Page 46: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

%48

4.2

484.

254

4.7

20.

229

2.5

24:

1 (

N=1

149)

- 120 -

Page 47: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

:A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

6831

542

584

31

1316

84

358

317

42%

69.7

85.7

90.6

100.

010

0.0

100.

092

.949

.050

.042

.955

.260

.065

.461

.80.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

00.

01.

00.

0%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

3.8

0.0

50

70

00

01

00

120

05

%1.

10.

010

.90.

00.

00.

00.

00.

30.

00.

011

.40.

00.

07.

456

415

31

05

452

024

15

9%

12.4

8.2

23.4

75.0

33.3

0.0

35.7

13.1

25.0

0.0

22.9

20.0

19.2

13.2

135

1530

00

06

871

030

110

27%

29.9

30.6

46.9

0.0

0.0

0.0

42.9

25.4

12.5

0.0

28.6

20.0

38.5

39.7

150

148

01

13

992

325

25

15%

33.2

28.6

12.5

0.0

33.3

100.

021

.428

.925

.042

.923

.840

.019

.222

.184

124

11

00

561

310

14

7%

18.6

24.5

6.3

25.0

33.3

0.0

0.0

16.3

12.5

42.9

9.5

20.0

15.4

10.3

164

00

00

029

11

00

01

%3.

58.

20.

00.

00.

00.

00.

08.

512

.514

.30.

00.

00.

01.

56

00

00

00

261

04

02

4%

1.3

0.0

0.0

0.0

0.0

0.0

0.0

7.6

12.5

0.0

3.8

0.0

7.7

5.9

181

840

22

09

224

56

683

1937

%40

.016

.362

.550

.066

.70.

064

.365

.362

.585

.764

.860

.073

.154

.414

210

293

11

310

41

135

212

18%

31.4

20.4

45.3

75.0

33.3

100.

021

.430

.312

.514

.333

.340

.046

.226

.534

526

352

10

433

20

112

327

%76

.353

.154

.750

.033

.30.

028

.69.

625

.00.

010

.540

.011

.539

.785

1117

00

00

362

013

02

12%

18.8

22.4

26.6

0.0

0.0

0.0

0.0

10.5

25.0

0.0

12.4

0.0

7.7

17.6

225

2212

01

01

241

05

03

16%

49.8

44.9

18.8

0.0

33.3

0.0

7.1

7.0

12.5

0.0

4.8

0.0

11.5

23.5

9711

91

10

176

21

301

811

%21

.522

.414

.125

.033

.30.

07.

122

.225

.014

.328

.620

.030

.816

.225

039

331

21

1120

34

664

114

39%

55.3

79.6

51.6

25.0

66.7

100.

078

.659

.250

.085

.761

.020

.053

.857

.4

26p<

0.00

1

p=0.

012

p<0.

001

p=0.

779

p=0.

212

31.4

532626

2

20.2

58

114.

889

128.

026

206.

563

25:

1N

=114

9

10 20 30 40 50 60

70

p*

27.1

4413

266.

341

2626 1321

.034

431.

591

13p<

0.00

1

p<0.

001

p<0.

001

p0.

072

df 78

%48

4.2

484.

254

4.7

20.

229

2.5

24:

1 (

N=1

149)

- 121 -

Page 48: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

689

40

00

00

271

08

05

1%

2.0

8.2

0.0

0.0

0.0

0.0

0.0

7.9

12.5

0.0

7.6

0.0

19.2

1.5

607

161

00

382

22

250

912

%13

.314

.325

.025

.00.

00.

021

.423

.925

.028

.623

.80.

034

.617

.632

333

393

20

926

25

383

211

42%

71.5

67.3

60.9

75.0

66.7

0.0

64.3

76.4

62.5

42.9

79.0

40.0

42.3

61.8

71

20

10

015

01

80

12

%1.

52.

03.

10.

033

.30.

00.

04.

40.

014

.37.

60.

03.

82.

93

11

00

00

240

04

02

4%

0.7

2.0

1.6

0.0

0.0

0.0

0.0

7.0

0.0

0.0

3.8

0.0

7.7

5.9

130

1314

00

12

120

17

08

11%

28.8

26.5

21.9

0.0

0.0

100.

014

.33.

50.

014

.36.

70.

030

.816

.27

22

00

00

10

01

01

2%

1.5

4.1

3.1

0.0

0.0

0.0

0.0

0.3

0.0

0.0

1.0

0.0

3.8

2.9

8112

90

10

27

01

00

316

%17

.924

.514

.10.

033

.30.

014

.32.

00.

014

.30.

00.

011

.523

.55

10

00

00

60

11

00

0%

1.1

2.0

0.0

0.0

0.0

0.0

0.0

1.7

0.0

14.3

1.0

0.0

0.0

0.0

*

F1x.

8

33.0

42

24.1

90

29.0

64

111.

672

13

10.1

57

p=0.

006

F1x.

0

F1x.

1

F1x.

2

F1x.

3

F1x.

4

F1x.

5

ICD

-10

F1x.

6

F1x.

713

2df

p*

37.5

01

25.7

75

p<0.

001

p=0.

681

27:

1IC

D-1

0 F1

N=1

149

84.2

90

13.4

99

p<0.

001

p=0.

410

p<0.

001

p=0.

018

p=0.

002

p=0.

029

13 13 13 13 13 13 13

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

6854

319

10

01

70

01

01

2%

11.9

6.1

29.7

25.0

0.0

0.0

7.1

2.0

0.0

0.0

1.0

0.0

3.8

2.9

123

216

02

02

10

00

00

6%

27.2

4.1

25.0

0.0

66.7

0.0

14.3

0.3

0.0

0.0

0.0

0.0

0.0

8.8

270

20

00

02

00

00

00

%6.

00.

03.

10.

00.

00.

00.

00.

60.

00.

00.

00.

00.

00.

08

00

00

00

40

00

00

2%

1.8

0.0

0.0

0.0

0.0

0.0

0.0

1.2

0.0

0.0

0.0

0.0

0.0

2.9

245

327

30

13

00

00

12

11%

54.2

6.1

42.2

75.0

0.0

100.

021

.40.

00.

00.

00.

020

.07.

716

.24

10

00

01

271

40

54

624

%0.

92.

00.

00.

00.

00.

07.

179

.050

.00.

04.

880

.023

.135

.32

00

01

00

114

15

21

710

%0.

40.

00.

00.

033

.30.

00.

033

.212

.571

.41.

920

.026

.914

.70.

00.

00.

00.

00.

00.

00.

08.

03.

00.

075

.00.

01.

010

.0%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.3

37.5

0.0

71.4

0.0

3.8

14.7

41.0

3.0

5.0

0.0

0.0

0.0

6.0

10.0

0.0

2.0

10.0

1.0

3.0

4.0

%9.

16.

17.

80.

00.

00.

042

.92.

90.

028

.69.

520

.011

.55.

91.

028

.01.

00.

00.

00.

01.

00.

00.

00.

025

.00.

06.

07.

0%

0.2

57.1

1.6

0.0

0.0

0.0

7.1

0.0

0.0

0.0

23.8

0.0

23.1

10.3

1.0

3.0

2.0

0.0

0.0

0.0

0.0

3.0

1.0

0.0

0.0

0.0

1.0

3.0

%0.

26.

13.

10.

00.

00.

00.

00.

912

.50.

00.

00.

03.

84.

4

13p<

0.00

1

33.2

2213

p=0.

002

254.

425

13p<

0.00

1

623.

632

13p<

0.00

1

46.3

2513

p<0.

001

354.

379

387.

687

13p<

0.00

1

698.

785

13p<

0.00

1

32.4

0213

p=0.

002

6.35

413

p=0.

932

83.3

0513

p<0.

001

170.

717

13p<

0.00

1

26:

1N

=114

9

2df

p*

- 122 -

Page 49: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

689

40

00

00

271

08

05

1%

2.0

8.2

0.0

0.0

0.0

0.0

0.0

7.9

12.5

0.0

7.6

0.0

19.2

1.5

607

161

00

382

22

250

912

%13

.314

.325

.025

.00.

00.

021

.423

.925

.028

.623

.80.

034

.617

.632

333

393

20

926

25

383

211

42%

71.5

67.3

60.9

75.0

66.7

0.0

64.3

76.4

62.5

42.9

79.0

40.0

42.3

61.8

71

20

10

015

01

80

12

%1.

52.

03.

10.

033

.30.

00.

04.

40.

014

.37.

60.

03.

82.

93

11

00

00

240

04

02

4%

0.7

2.0

1.6

0.0

0.0

0.0

0.0

7.0

0.0

0.0

3.8

0.0

7.7

5.9

130

1314

00

12

120

17

08

11%

28.8

26.5

21.9

0.0

0.0

100.

014

.33.

50.

014

.36.

70.

030

.816

.27

22

00

00

10

01

01

2%

1.5

4.1

3.1

0.0

0.0

0.0

0.0

0.3

0.0

0.0

1.0

0.0

3.8

2.9

8112

90

10

27

01

00

316

%17

.924

.514

.10.

033

.30.

014

.32.

00.

014

.30.

00.

011

.523

.55

10

00

00

60

11

00

0%

1.1

2.0

0.0

0.0

0.0

0.0

0.0

1.7

0.0

14.3

1.0

0.0

0.0

0.0

*

F1x.

8

33.0

42

24.1

90

29.0

64

111.

672

13

10.1

57

p=0.

006

F1x.

0

F1x.

1

F1x.

2

F1x.

3

F1x.

4

F1x.

5

ICD

-10

F1x.

6

F1x.

713

2df

p*

37.5

01

25.7

75

p<0.

001

p=0.

681

27:

1IC

D-1

0 F1

N=1

149

84.2

90

13.4

99

p<0.

001

p=0.

410

p<0.

001

p=0.

018

p=0.

002

p=0.

029

13 13 13 13 13 13 13

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

6854

319

10

01

70

01

01

2%

11.9

6.1

29.7

25.0

0.0

0.0

7.1

2.0

0.0

0.0

1.0

0.0

3.8

2.9

123

216

02

02

10

00

00

6%

27.2

4.1

25.0

0.0

66.7

0.0

14.3

0.3

0.0

0.0

0.0

0.0

0.0

8.8

270

20

00

02

00

00

00

%6.

00.

03.

10.

00.

00.

00.

00.

60.

00.

00.

00.

00.

00.

08

00

00

00

40

00

00

2%

1.8

0.0

0.0

0.0

0.0

0.0

0.0

1.2

0.0

0.0

0.0

0.0

0.0

2.9

245

327

30

13

00

00

12

11%

54.2

6.1

42.2

75.0

0.0

100.

021

.40.

00.

00.

00.

020

.07.

716

.24

10

00

01

271

40

54

624

%0.

92.

00.

00.

00.

00.

07.

179

.050

.00.

04.

880

.023

.135

.32

00

01

00

114

15

21

710

%0.

40.

00.

00.

033

.30.

00.

033

.212

.571

.41.

920

.026

.914

.70.

00.

00.

00.

00.

00.

00.

08.

03.

00.

075

.00.

01.

010

.0%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

2.3

37.5

0.0

71.4

0.0

3.8

14.7

41.0

3.0

5.0

0.0

0.0

0.0

6.0

10.0

0.0

2.0

10.0

1.0

3.0

4.0

%9.

16.

17.

80.

00.

00.

042

.92.

90.

028

.69.

520

.011

.55.

91.

028

.01.

00.

00.

00.

01.

00.

00.

00.

025

.00.

06.

07.

0%

0.2

57.1

1.6

0.0

0.0

0.0

7.1

0.0

0.0

0.0

23.8

0.0

23.1

10.3

1.0

3.0

2.0

0.0

0.0

0.0

0.0

3.0

1.0

0.0

0.0

0.0

1.0

3.0

%0.

26.

13.

10.

00.

00.

00.

00.

912

.50.

00.

00.

03.

84.

4

13p<

0.00

1

33.2

2213

p=0.

002

254.

425

13p<

0.00

1

623.

632

13p<

0.00

1

46.3

2513

p<0.

001

354.

379

387.

687

13p<

0.00

1

698.

785

13p<

0.00

1

32.4

0213

p=0.

002

6.35

413

p=0.

932

83.3

0513

p<0.

001

170.

717

13p<

0.00

1

26:

1N

=114

9

2df

p*

- 123 -

Page 50: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

6822

20

00

01

331

110

04

9%

4.9

4.1

0.0

0.0

0.0

0.0

7.1

9.6

12.5

14.3

9.5

0.0

15.4

13.2

122

00

00

011

00

30

14

%2.

74.

10.

00.

00.

00.

00.

03.

20.

00.

02.

90.

03.

85.

92

10

00

00

60

01

01

0%

0.4

2.0

0.0

0.0

0.0

0.0

0.0

1.7

0.0

0.0

1.0

0.0

3.8

0.0

30

00

00

013

00

40

10

%0.

70.

00.

00.

00.

00.

00.

03.

80.

00.

03.

80.

03.

80.

00

00

00

00

00

00

01

1%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

3.8

1.5

60

00

00

17

11

20

04

%1.

30.

00.

00.

00.

00.

07.

12.

012

.514

.31.

90.

00.

05.

9

p=0.

165

28.5

9413

p=0.

007

22.0

4113

p=0.

055

*

21.3

3613

p=0.

067

5.90

313

p=0.

950

8.10

913

p=0.

836

17.8

1513

29:

1N

=114

9

2df

p

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

684

20

00

00

70

00

03

4%

0.9

4.1

0.0

0.0

0.0

0.0

0.0

2.0

0.0

0.0

0.0

0.0

11.5

5.9

458

80

00

418

00

60

213

%10

.016

.312

.50.

00.

00.

028

.65.

20.

00.

05.

70.

07.

719

.157

94

00

03

953

521

15

16%

12.6

18.4

6.3

0.0

0.0

0.0

21.4

27.7

37.5

71.4

20.0

20.0

19.2

23.5

387

40

00

183

30

290

310

%8.

414

.36.

30.

00.

00.

07.

124

.237

.50.

027

.60.

011

.514

.715

12

01

00

160

05

01

0%

3.3

2.0

3.1

0.0

33.3

0.0

0.0

4.7

0.0

0.0

4.8

0.0

3.8

0.0

394

40

00

045

01

221

59

%8.

68.

26.

30.

00.

00.

00.

013

.10.

014

.321

.020

.019

.213

.225

30

00

00

91

06

00

2%

5.5

6.1

0.0

0.0

0.0

0.0

0.0

2.6

12.5

0.0

5.7

0.0

0.0

2.9

172

70

00

122

10

90

12

%3.

84.

110

.90.

00.

00.

07.

16.

412

.50.

08.

60.

03.

82.

919

22

20

00

60

05

10

2%

4.2

4.1

3.1

50.0

0.0

0.0

0.0

1.7

0.0

0.0

4.8

20.0

0.0

2.9

2df

p

F028

.837

13

F513

.773

13

p=0.

007

F352

.680

13p<

0.00

1

F229

.668

13p=

0.00

5

p=0.

390

F460

.929

13p<

0.00

1

p=0.

050

F712

.689

13p=

0.47

2

*

28:

1IC

D-1

0N

=114

9

F812

.093

13p=

0.52

0

F937

.234

13p<

0.00

1

F622

.344

13

- 124 -

Page 51: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

6822

20

00

01

331

110

04

9%

4.9

4.1

0.0

0.0

0.0

0.0

7.1

9.6

12.5

14.3

9.5

0.0

15.4

13.2

122

00

00

011

00

30

14

%2.

74.

10.

00.

00.

00.

00.

03.

20.

00.

02.

90.

03.

85.

92

10

00

00

60

01

01

0%

0.4

2.0

0.0

0.0

0.0

0.0

0.0

1.7

0.0

0.0

1.0

0.0

3.8

0.0

30

00

00

013

00

40

10

%0.

70.

00.

00.

00.

00.

00.

03.

80.

00.

03.

80.

03.

80.

00

00

00

00

00

00

01

1%

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

0.0

3.8

1.5

60

00

00

17

11

20

04

%1.

30.

00.

00.

00.

00.

07.

12.

012

.514

.31.

90.

00.

05.

9

p=0.

165

28.5

9413

p=0.

007

22.0

4113

p=0.

055

*

21.3

3613

p=0.

067

5.90

313

p=0.

950

8.10

913

p=0.

836

17.8

1513

29:

1N

=114

9

2df

p

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

684

20

00

00

70

00

03

4%

0.9

4.1

0.0

0.0

0.0

0.0

0.0

2.0

0.0

0.0

0.0

0.0

11.5

5.9

458

80

00

418

00

60

213

%10

.016

.312

.50.

00.

00.

028

.65.

20.

00.

05.

70.

07.

719

.157

94

00

03

953

521

15

16%

12.6

18.4

6.3

0.0

0.0

0.0

21.4

27.7

37.5

71.4

20.0

20.0

19.2

23.5

387

40

00

183

30

290

310

%8.

414

.36.

30.

00.

00.

07.

124

.237

.50.

027

.60.

011

.514

.715

12

01

00

160

05

01

0%

3.3

2.0

3.1

0.0

33.3

0.0

0.0

4.7

0.0

0.0

4.8

0.0

3.8

0.0

394

40

00

045

01

221

59

%8.

68.

26.

30.

00.

00.

00.

013

.10.

014

.321

.020

.019

.213

.225

30

00

00

91

06

00

2%

5.5

6.1

0.0

0.0

0.0

0.0

0.0

2.6

12.5

0.0

5.7

0.0

0.0

2.9

172

70

00

122

10

90

12

%3.

84.

110

.90.

00.

00.

07.

16.

412

.50.

08.

60.

03.

82.

919

22

20

00

60

05

10

2%

4.2

4.1

3.1

50.0

0.0

0.0

0.0

1.7

0.0

0.0

4.8

20.0

0.0

2.9

2df

p

F028

.837

13

F513

.773

13

p=0.

007

F352

.680

13p<

0.00

1

F229

.668

13p=

0.00

5

p=0.

390

F460

.929

13p<

0.00

1

p=0.

050

F712

.689

13p=

0.47

2

*

28:

1IC

D-1

0N

=114

9

F812

.093

13p=

0.52

0

F937

.234

13p<

0.00

1

F622

.344

13

- 125 -

Page 52: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

n=64

n=44

5842

%91

.695

.56

2%

9.4

4.5

70

%10

.90.

015

7%

23.4

15.9

3023

%46

.952

.38

10%

12.5

22.7

42

%6.

34.

50

2%

0.0

4.5

4030

%62

.568

.129

14%

45.3

31.8

3518

%54

.740

.917

13%

26.6

29.5

124

%18

.89.

09

8%

14.0

18.1

3328

%51

.663

.6

1 1 2 2 1

1.98

1

0.11

6

2.51

9

1.27

8

1.54

6

p=0.

159

p=0.

734

p=0.

284

p=0.

528

p=0.

214

p=0.

065

p=0.

771

p=0.

159

108

108

108

10.3

755

0.52

02 1

1.98

1

108

31:

N=1

081

p=0.

346

Np*

2df

0.88

71

10 20 30 40 50 60

108

108

108

108

108

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

6834

08

10

02

00

01

00

2%

7.5

0.0

12.5

25.0

0.0

0.0

14.3

0.0

0.0

0.0

1.0

0.0

0.0

2.9

370

40

00

02

00

10

22

%8.

20.

06.

30.

00.

00.

00.

00.

60.

00.

01.

00.

07.

72.

940

16

00

00

10

01

10

4%

8.8

2.0

9.4

0.0

0.0

0.0

0.0

0.3

0.0

0.0

1.0

20.0

0.0

5.9

00

10

00

01

00

00

00

%0.

00.

01.

60.

00.

00.

00.

00.

30.

00.

00.

00.

00.

00.

016

.01.

04.

00.

00.

00.

00.

03.

01.

00.

02.

00.

00.

02.

0%

3.5

2.0

6.3

0.0

0.0

0.0

0.0

0.9

12.5

0.0

1.9

0.0

0.0

2.9

14.3

4813

p=0.

350

45.3

8213

p<0.

001

8.66

713

p=0.

798

53.8

6813

p<0.

001

37.6

5613

p<0.

001

30:

1N

=114

9

2df

p*

- 126 -

Page 53: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

n=64

n=44

5842

%91

.695

.56

2%

9.4

4.5

70

%10

.90.

015

7%

23.4

15.9

3023

%46

.952

.38

10%

12.5

22.7

42

%6.

34.

50

2%

0.0

4.5

4030

%62

.568

.129

14%

45.3

31.8

3518

%54

.740

.917

13%

26.6

29.5

124

%18

.89.

09

8%

14.0

18.1

3328

%51

.663

.6

1 1 2 2 1

1.98

1

0.11

6

2.51

9

1.27

8

1.54

6

p=0.

159

p=0.

734

p=0.

284

p=0.

528

p=0.

214

p=0.

065

p=0.

771

p=0.

159

108

108

108

10.3

755

0.52

02 1

1.98

1

108

31:

N=1

081

p=0.

346

Np*

2df

0.88

71

10 20 30 40 50 60

108

108

108

108

108

MD

MA

: A

DH

D

n=45

2n=

49n=

64n=

4n=

3n=

1n=

14n=

343

n=8

n=7

n=10

5n=

5n=

26n=

6834

08

10

02

00

01

00

2%

7.5

0.0

12.5

25.0

0.0

0.0

14.3

0.0

0.0

0.0

1.0

0.0

0.0

2.9

370

40

00

02

00

10

22

%8.

20.

06.

30.

00.

00.

00.

00.

60.

00.

01.

00.

07.

72.

940

16

00

00

10

01

10

4%

8.8

2.0

9.4

0.0

0.0

0.0

0.0

0.3

0.0

0.0

1.0

20.0

0.0

5.9

00

10

00

01

00

00

00

%0.

00.

01.

60.

00.

00.

00.

00.

30.

00.

00.

00.

00.

00.

016

.01.

04.

00.

00.

00.

00.

03.

01.

00.

02.

00.

00.

02.

0%

3.5

2.0

6.3

0.0

0.0

0.0

0.0

0.9

12.5

0.0

1.9

0.0

0.0

2.9

14.3

4813

p=0.

350

45.3

8213

p<0.

001

8.66

713

p=0.

798

53.8

6813

p<0.

001

37.6

5613

p<0.

001

30:

1N

=114

9

2df

p*

- 127 -

Page 54: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

n=64

n=44

00

%0.

00.

016

8%

25.0

18.2

3925

%60

.956

.82

0%

3.1

0.0

10

%1.

60.

014

6%

21.9

13.6

20

%3.

10.

09

17%

14.1

38.6

00

%0.

00.

0

0.70

1

0.18

3

1.40

1

0.69

4

p=0.

279

1 11

p*

p0.

402

p0.

669

1 1 1 1

p0.

237

p=0.

405

F1x.

0

F1x.

1

2df

ICD

-10

F1x.

6

F1x.

7

F1x.

2

F1x.

3

F1x.

4

F1x.

5

33:

N=1

081

ICD

-10

F1

*

F1x.

8

p=0.

237

p=0.

003

1.17

3

1.40

1

8.61

4

n=64

n=44

3926

%60

.959

.116

12%

25.0

27.3

93

%14

.16.

80

0%

0.0

0.0

108

1.38

51

p=0.

239

108

108

0.70

01

p=0.

791

108

0.03

7

32:

N=1

081

1p=

0.84

7

N2

dfp*

- 128 -

Page 55: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

n=64

n=44

00

%0.

00.

016

8%

25.0

18.2

3925

%60

.956

.82

0%

3.1

0.0

10

%1.

60.

014

6%

21.9

13.6

20

%3.

10.

09

17%

14.1

38.6

00

%0.

00.

0

0.70

1

0.18

3

1.40

1

0.69

4

p=0.

279

1 11

p*

p0.

402

p0.

669

1 1 1 1

p0.

237

p=0.

405

F1x.

0

F1x.

1

2df

ICD

-10

F1x.

6

F1x.

7

F1x.

2

F1x.

3

F1x.

4

F1x.

5

33:

N=1

081

ICD

-10

F1

*

F1x.

8

p=0.

237

p=0.

003

1.17

3

1.40

1

8.61

4

n=64

n=44

3926

%60

.959

.116

12%

25.0

27.3

93

%14

.16.

80

0%

0.0

0.0

108

1.38

51

p=0.

239

108

108

0.70

01

p=0.

791

108

0.03

7

32:

N=1

081

1p=

0.84

7

N2

dfp*

- 129 -

Page 56: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

n=64

n=44

80

%12

.50.

04

2%

6.3

4.5

61

%9.

42.

31

0%

1.6

0.0

35:

N=1

081

N2

dfp*

108

0.14

41

p=0.

704

108

5.94

01

p=0.

015

108

2.17

01

p=0.

141

108

0.69

41

p=0.

405

192

47%

45.9

55.3

01

%0.

02.

38

13%

12.5

29.5

45

%6.

311

.44

4%

6.3

9.1

21

%3.

12.

34

2%

6.3

4.5

00

%0.

00.

07

5%

10.9

11.4

20

%3.

10.

0

34:

N=1

081

ICD

-10

2df

pn=

64n=

44

90.7

435

p<0.

001

F01.

468

1p=

0.22

6

F30.

893

1p=

0.34

5

F24.

837

1p=

0.02

8

F50.

070

1p=

0.79

1

F40.

307

1p=

0.58

0

F7F60.

144

1p=

0.70

4

F80.

005

1p=

0.94

5

F91.

401

1p=

0.23

7

- 130 -

Page 57: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

n=64

n=44

80

%12

.50.

04

2%

6.3

4.5

61

%9.

42.

31

0%

1.6

0.0

35:

N=1

081

N2

dfp*

108

0.14

41

p=0.

704

108

5.94

01

p=0.

015

108

2.17

01

p=0.

141

108

0.69

41

p=0.

405

192

47%

45.9

55.3

01

%0.

02.

38

13%

12.5

29.5

45

%6.

311

.44

4%

6.3

9.1

21

%3.

12.

34

2%

6.3

4.5

00

%0.

00.

07

5%

10.9

11.4

20

%3.

10.

0

34:

N=1

081

ICD

-10

2df

pn=

64n=

44

90.7

435

p<0.

001

F01.

468

1p=

0.22

6

F30.

893

1p=

0.34

5

F24.

837

1p=

0.02

8

F50.

070

1p=

0.79

1

F40.

307

1p=

0.58

0

F7F60.

144

1p=

0.70

4

F80.

005

1p=

0.94

5

F91.

401

1p=

0.23

7

- 131 -

Page 58: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

1583432161512121010

6666544

PA/PL/ PL 33222

37: 2

243188154111

5848454239352914

98887655535433

36: 2

- 132 -

Page 59: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

15834321615121210106666544

PA/PL/ PL 33222

37: 2

- 133 -

Page 60: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

1 2792 1513 1434 1405 1346 1307 1228 1228 107

10 8511 6512 6112 4414 4315 4116 3817 3718 3718 3418 3421 3322 3123 2824 2824 2624 2524 2528 20

38: 20

- 134 -

Page 61: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

1 2792 1513 1434 1405 1346 1307 1228 1228 10710 8511 6512 6112 4414 4315 4116 3817 3718 3718 3418 3421 3322 3123 2824 2824 2624 2524 2528 20

38: 20

- 135 -

Page 62: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

- 136 -

Page 63: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

- 137 -

Page 64: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

- 138 -

Page 65: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

- 139 -

Page 66: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

- 64 -- 140 -

Page 67: NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1*...NCNP - b(& &É $ª 0¿ > E . @6õ4 (& $L H b Â1* ... b--

- 64 - - 141 -


RADIOSS ),å½ § ¿a ~a÷¡îØí´ · RADIOSS ),å½_§ ¿a ~a÷¡îØí´ Ò\¬ 1 Kim H. Parker 2 x â1 1 ³t ÐÕÓC45SG?37: ¨ 2 Physiological Flow Studies Group, Department

GRANICA NASELJA ä PROMET - Rogoznicarogoznica.hr/nova/wp-content/uploads/2018/01/2.1... · rogoznica dvornica 5$ä$1-=(ý(92 podglavica jarebinjak zatoglav /2ä1,&(67,9$â1,&$ sapina

1 Â2( q - pref.hiroshima.lg.jp · >0 ¸6ë)% Z6õ 2( q ¹ B 29 º *Ë' 9 ¸6ë)% Z Â1* b +0[ yyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy y 53 '¨ 17 /² ¸6ë)% Z Â1* ¦ d X yyyyyyyyyyyyyyyyyyyyyyyyyyyyyyyy

*2',â1-,3/$1,352*5$05$'$ ]DãNROVNXJRGLQXss-prometno-tehnicka-si.skole.hr/upload/ss-prometno... · 2018-05-14 · 5 predmet poslovanja ± djelatnost predmet poslovanja - '-(/$71267,

>2>,'¨ G ¥ ³ P0ð : 3° í8× q#Ø 6õ4 0¿ b0i 9 6õ M 1* Z'¼ · 22 >2>,'¨ G ¥ ³ P0ð _ : 3° í8× q#Ø 6õ4 0¿ b0i 9 _ 6õ M 1* Z'¼ '¨ G ¥ ³ P0ð6ä &*c ¥ b ¹ B º

*2',â1-,3/$1,352*5$05$'$â.2/(=$â.2/6.8 ./2017 . GODINUos-jkozarac-soljani.skole.hr/upload/os-jkozarac...261291$â.2/$Ä JOSIP KOZARAC ³ SOLJANI *2',â1-,3/$1,352*5$05$'$â.2/(=$â.2/6.8

GNE 2009 Remudy MDCTN Core dataset for CCNMD 2 NCNP QRS

ISKUSTVA U PRIMENI PRAVILNIKA O ENERGETSKOJ … · POTROŠNJA ENERGIJE 6$'$â1-$3 2752â1-$(1(5*,-(38% 34% 28% u zgradama (grejanje, klimatizacija, priprema sanitarne vode) industrija

3A7704G, Fusion PC スプレーガン, 指示, 日本人€¦ · 6õ4 b1  i 3A7704G 3 6õ4 b1  i,e1 "' b 1  i 1  309550 Fusion AP « É Þ î å v 1  i 3A7318 Fusion PC

AÒ â1( 5%ZZZ NKGDZ FRP - Shandong Universitycourse.sdu.edu.cn/Download2/a576c358-75a6-44e0-a14c-835...AÒ â1( 5%ZZZ NKGDZ FRP AÒ â1( 5%ZZZ NKGDZ FRP Title SSReader Print. Author

9,-(û8 9,-(û8 (85236.2-65(',â1-2-%$1&,,(8526.83,1 ......makroekonomska stabilnost i zdrave javne financije. Komisija je u isto vrijeme objavila Izvješće o mehanizmu upozoravanja

NCNP Medical News · 2018. 8. 9. · NCNP Medical News . ADHD . Title: NCNP診療ニュースNo.2 Author: NCNP Created Date: 1/12/2018 9:09:56 AM

Â748¦+Ð&6,1+'ô7+, 0Ð17+, 7,Â1*$1+ - hexagon.edu.vn1).pdf · 4 a028 lÊ hoÀng thu anh 07.09.1998 12a10 nhân chính 0Ð17+, 7,Â1*$1+ ... 9 a057 1*8

バイオバンク ～次世代の医療のために～24 National Center of Neurology and Psychiatry (NCNP )National Center of Neurology and Psychiatry NCNP 25 バイオバンク～次世代の医療のために～

20122013 · 2014. 3. 13. · 20122013 34 National Center of Neurology and Psychiatry (NCNP) National Center of Neurology and Psychiatry (NCNP) 35 NCNPの活動 2012–2013 社会とNCNPをつなぐ広報活動、NCNPの資源を生かした

Japan Atomic Energy Agency - JOPSSjolissrch-inter.tokai-sc.jaea.go.jp/pdfdata/JAEA...y ß é. 5ô xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx .â1 xxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxxx

*2’,â1-(,=9-(âß( 0,1,67$5679$ ),1$1&,-$ =$ ˝˝˝ *2’,18 · 2679$5(1-(5$6+2’$’5å$912*3525$þ81$8 ˝˝˝ *2’,1, ˙ 7(.8ü,5$6+2’, ˙

85’Â1 .(5İ’( İ/6(/ $./$Ş5 *HUçNOşWLULOPHVLQH · 2016. 8. 22. · 1. ULUSLARARASI KUR’ĀN’I YENİDEN DÜŞÜNME İLMĪ TOPLANTISI 1ST INTERNATIONAL SYMPOSIUM ON RETHINKING

2 CRT - NCNP · 2012-09-20 · Advancing patient’s health through learning, discovery and communication. NCNP Translational Medical Center Clinical Research Track TMC CRT Translational

8 < 2 Ç A4E ¥ 6õ M Â1* Ì iž営利...D X b ì1 0¿ －9－ >&>1>'8 < 2 Ç A4E ¥ _6õ M Â1* $ ( b0¿*( í1* % $× 1* P1ß 1* m 2 1* ) Ý b o Î ^ ] _ X 8 Z 1 >&>2>

N• 532. L• numéro : 75 centime• VENDREDI ourquoiPas?l.TOllZJbU!: AN!'â1. - N• 532. L• numéro : 75 centime• VENDREDI 1 ÜOTOBRp; 1924. ourquoiPas? GA/..E'JTE HEBDOMADAIRE

dspace.bcucluj.rodspace.bcucluj.ro/bitstream/123456789/67968/1/... · DE PROF. D-r HURMUZESCU C Â1 timp va mai străluci oare soarelei Cu toate că această chestiune nu reclamă

ù 8 8 ð - 8 + { > ºÅr ¢ ÿ ä » £ Ù { Õ µ r } ¨ G É r · et ¹3ûfþ b Ý æ fø4) b% g:g^gxg gg 58 6õ4 m*ñ 58 6õ4 ezgtg1g gog g>g gcg5g{g h tfh d Øfþ _ ° • ¶fþta

PRAVILNIK 281875$â1-2-25*$1 ... - unmo.ba · 8QLYHU]LWHW'åHPDO%LMHGLüX 0RVWDUX Pravilnik o sistematizaciji radnih mjesta Stranica 3 od 37 ýODQ (Poslovna etika ) Zaposlenici Univerziteta

8 < 2 Ç A4E ¥ 6õ M Â1* Ì i...>0>.>/>3 º>1 v 8 < 2 Ç A4E ¥ _6õ M Â1* $ ( 8 < 2 Ç A4E ¥ _6õ M Â1* Ì i % 2 K 2 Ç % 2 Ç 1 "I 8 < q · 2 Ç ¥

9 b 6 M ('¼ | 5 &É% b M0t/² · S6Û&É% S6Û&É% 8× ß/æ1= º 8× 6õ4 û x \ í%4 b/ ;6õ4 µ6õ'¼ [ b ») 9 w M M ( @ 8× _ > E ß/æ þ b z m x6õ4 M &k í 2 D Ø b · ¥

NCNP) AMED) RIKEN) · 2020. 8. 24. · 2020 年8月25 日 国立研究開発法人国立精神・神経医療研究センター（ncnp) 国立研究開発法人日本医療研究開発機構（amed)

2( qH >Ì FãG G F÷Fþ) ) H 6õ4 2( qH · 2( qh >Ìfãg g f÷fþ) ) h 6õ4 2( qh h h ... ¶ ¸9 9 6×'¼h f¸%&1/ (h 2 #Õ q%&1/ (f¸ º3û ¦ >%&1/ (f¸7÷ a º%&1/ ('¼h f¸ æ

平成24年度 NCNP原著論文一覧表平成24年度 NCNP原著論文一覧表 著者、発表者等 論文名、演題名等 掲載誌、学会等 成果又は特記事項 1 Teraishi

Ê ³ Ü Æ - mhlw.go.jp · B 8o% H 6õ4 B 8o% H 6õ4 B 8o% H H 6õ4 B 8o% H H 6õ4 H )r 0Û oFûFÚFáG ¹3û ¦8oH H F· ¶ ¦ Fþ"g #Fþ0Û oFû ¹3ûFþ0i!l F·F· ¶ ¦ Fþ"g

Presentatie "Overtuigend schrijven" (NCNP Summit 2014)

9,-(û8 9,-(û8 (85236.2-65(',â1-2-%$1&,,(8526.83,1

;F+EÑ k Ãg®W3 I :C 7 ñR Â1 pFþà o$o6î N ÂÆÎ7 é{YíÀ° · Title;F+EÑ k Ãg®W3 I :C 7 ñR Â1 pFþà o$o6î N ÂÆÎ7 é{YíÀ° §§ Author B)Sß Created

*2',â1-, 3/$1 , 352*5$0 2'*2-12 2%5$=2912* 5$'$ 35('â.2/( · 2019. 11. 15. · 3uhgãnrod sul 2â 2uhkrylfd ânrovnd xolfd 2uhkrylfd 7ho id[ ( pdlo xuhg#rv ruhkrylfd vnroh ku *2',â1-,

9,-(û8 9,-(û8 (85236.2-65(',â1-2-%$1&,,(8526.83,1 ......Grafikon 4.3.6.: Odabrani pokazatelji obrazovanja za Hrvatsku i EU (2018.) 44 Grafikon 4.4.1.: Kretanje ukupne faktorske